Drug, bio-affecting and body treating compositions inventions 05/08

20080125347 - Amino acid substituted molecules: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also... Agent: Seed Intellectual Property Law Group PLLC

20080125350 - Branched polyalkylene glycols: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and... Agent: Fitzpatrick Cella Harper & Scinto

20080125346 - Infant formula: The present invention relates to a nutritional composition containing protein, fat and carbohydrate; and a. a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (NpxN); and b. a non-proteinaceous negatively charged, glycan or glycoconjugate component with... Agent: Foley And Lardner LLP Suite 500

20080125348 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080125349 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080125351 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080125352 - Unique integrin binding site in connective tissue growth factor: The invention relates to a connective tissue growth factor peptide that encompasses a CTGF binding site for an integrin such as αvβ3 or α5β1 and uses therefor. The invention also relates to agonists and inhibitors of the CTGF-integrin binding and methods of treating and preventing CTGF-related disorders.... Agent: Marshall, Gerstein & Borun LLP

20080125353 - Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus: Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080125354 - Selective inhibition of matrix metalloproteinases: Synthetic triple-helical peptides (THPs) are used for the design and synthesis of triple-helical transition state analog inhibitors. These inhibitors feature a phosphonate ester or phosphinic moiety in place of the scissle bond. These groups inhibit MMPs, and methods been developed for their convenient incorporation within a peptide sequence by solid-phase... Agent: Akerman Senterfitt

20080125359 - Antimicrobial peptides and methods of identifying the same: Antimicrobial peptides and methods of identifying the same are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20080125360 - Composition comprising pyy for the treatment of gastrointestinal disorders: The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of functional gastrointestinal disorders, such as irritable bowel disease and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080125357 - Compositions comprising a ligand of chemerinr: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related... Agent: Edwards Angell Palmer & Dodge LLP

20080125355 - Endogenous peptide and active subfragments thereof: The present invention relates to a substantially pure biologically active consecutive anti-angiogenic polypeptide comprising the central region of human Histidine Rich Glycoprotein (HRGP). Said polypeptide is shown to comprise a potential endogenous, naturally occurring subfragment of human HRGP, comprising similar anti-angiogenic activities as the mature protein. The present invention also... Agent: Fish & Richardson P.C.

20080125366 - Insecticidal proteins derived from bacillus thuringiensis: The present invention relates to the field of plant pest control, particularly insect control. Provided are nucleotide sequences from Bacillus thuringiensis encoding insecticidal proteins. Further provided are methods and means for using said nucleotide sequence for controlling plant insect pests. It is emphasized that this abstract is provided to comply... Agent: Buchanan, Ingersoll & Rooney PC

20080125365 - Isolated complexes of covalently cross-linked endotoxin and modified md-2: Applicants have produced and isolated chemically cross-linked complexes of endotoxin and modified MD-2, and have developed methods of using these complexes.... Agent: Viksnins Harris & Padys Pllp

20080125362 - Method of screening compound preventing cells from infection with hepatitis c virus (hcv): The present invention relates to a screening method and identification method for a compound that inhibits the cell infection of hepatitis C virus (HCV), which comprises measuring affinity of a test compound for fibroblast growth factor receptor (FGFR) or the capability of blocking the binding thereof to HCV, and selecting... Agent: Fitzpatrick Cella Harper & Scinto

20080125368 - Methods: A method for aiding in the assessment of peritoneal membrane injury or complications of peritoneal dialysis in a patient, the method comprising the step of determining the level of CCL18 and/or angiogenin in a sample from the patient. The method may be for assessing the likely progression of peritoneal membrane... Agent: Nikolai & Mersereau, P.A.

20080125364 - Methods and compositions for treating epithelial cancers: Methods and compositions for modulating tight junction formation are provided.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080125358 - Methods for chk2 inhibitor patient selection: The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids,... Agent: Peter G. Carroll Medlen & Carroll LLP

20080125363 - Polymer-linked pseudomonas exotoxin immunotoxin: The present invention relates to polymer conjugates of SS1P, and methods of making using the same.... Agent: Bozicevic, Field & Francis LLP

20080125369 - Soluble t cell receptors: The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCRα chain, except the transmembrane domain thereof, and (ii) all or part of a TCR β chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and... Agent: Banner & Witcoff, Ltd.

20080125361 - Stable formulations of peptides: Stable pharmaceutical composition comprising insulinotropic peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080125356 - Stable growth hormone liquid formulation: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of... Agent: Pharmacia Corporation Global Patent Department

20080125370 - Use of gelsolin to treat infections: The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.... Agent: Wolf Greenfield & Sacks, P.C.

20080125372 - Biologically active peptide vapeehptllteaplnpk derivatives: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.... Agent: EagleIPLimited

20080125373 - Mntf peptides and compositions and methods of use: The present invention is directed to novel peptides and compositions capable of modulating viability and growth in neuronal cells, and to methods of modulating neuronal cell viablility and growth employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to novel peptide analogues of... Agent: Duane Morris LLP

20080125371 - Specific antagonists for glucose-dependent insulinotropic polypeptide (gip): In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II)... Agent: Edwards Angell Palmer & Dodge LLP

20080125374 - Gd3-mimetic peptides: GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an anti-GD3 antibody; and medicinal compositions containing... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080125375 - Protease inhibitors: This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080125376 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said... Agent: Michael C. Badia Vertex Pharmaceuticals Incorporated

20080125377 - Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are formulations which deliver a variety of therapeutic agents, including but not... Agent: Bausch & Lomb Incorporated

20080125378 - Use of amygdalin analogues for the treatment of psoriasis: The compounds of formula (1), wherein n is an integer from 0 to 4; R1 is a radical selected from the group consisting of H, CH3, CH2-CH3, C(CH3)3, COOH, CONH2 and C=CH; R2, R3, R4 and R5 are radicals independently selected from the group consisting of H, F, Cl, Br,... Agent: Berenbaum, Weinshienk & Eason, P.c

20080125379 - Drug and food or drink for improving pancreatic functions: 3-O-β-D-Glucopyranosyl-4-methyl-ergost-7-en-3-ol or a composition containing 0.001 to 10% by dry mass of the aforementioned compound, which is an extract of a plant of the family Liliaceae or a fraction thereof containing the compound, is used as an active ingredient of a drug for improving pancreatic functions.... Agent: Knobbe Martens Olson & Bear LLP

20080125380 - Fatty acid-anticancer conjugates and uses thereof: The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.... Agent: Wolf Greenfield & Sacks, P.C.

20080125381 - Imidazopyridine derivatives: The present invention relates to a novel imidazo[4,5-b]pyridine derivative compound represented by Formula (I) and a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the above compound. The present invention further relates to a pharmaceutical composition comprising the above compound. The above compound has... Agent: Birch Stewart Kolasch & Birch

20080125387 - Anemia: Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient,... Agent: Frommer Lawrence & Haug

20080125382 - Extracellular superoxide dismutase (ec-sod) gene delivery to prevent oxidative injury: The present invention relates to compositions and methods for preventing oxidative injury to a cell. The compositions comprise a lipid formulation and a recombinant nucleic acid encoding an extracellular superoxide dismutase (EC-SOD), which upon transfection of a target cell is expressed by the cell and acts as an enzymatic antioxidant.... Agent: Townsend And Townsend And Crew, LLP

20080125389 - Men1 is a marker and therapeutic target for breast and prostate cancer: The present invention provides genomic markers for determining the presence or absence of breast cancer. The invention further demonstrates that inhibition of MEN1 reduces breast or prostate cancer proliferation, thereby demonstrating that inhibition of MEN1 activity or expression can be used to reduce breast cancer or prostate cancer proliferation in... Agent: Townsend And Townsend And Crew, LLP

20080125388 - Methods and compositions for cpg15-2: Disclosed herein are compositions of CPG 15-2 and methods for treating conditions of excessive cell death, such as neurological conditions, using such compositions. Compounds that inhibit the activity of CPG 15-2 are also disclosed herein for the treatment of conditions of undesirable cell survival, such as cancer.... Agent: Clark & Elbing LLP

20080125390 - Methods for modulating immune and inflammatory responses: A method for controlling leukaemia inhibitory factor (LIF)-interferon gamma inflammatory axis is provided. Control of interferon gamma production or release is mediated via modulation of the expression or activity of axotrophin (MARCH VII). Methods are provided for treating an animal that has received allografted tissue as well as for treating... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080125385 - Modulating phosphatase activity in cardiac cells: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve β-adrenergic responsiveness.... Agent: Ewards Angell Palmer & Dodge LLP (client: Mgh, Partners)

20080125383 - Modulators of coagulation factors with enhanced stability: The invention provides improved nucleic acid ligands with enhanced stability that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary... Agent: King & Spalding LLP

20080125386 - Rna interference agents for therapeutic use: The invention features chemically modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA. The features siRNA are effective therapeutics, particularly for targeting SOD1.... Agent: Lahive & Cockfield, LLP

20080125384 - Simultaneous silencing and restoration of gene function: Method and composition for simultaneously silencing an endogenously transcribed polynucleotide sequence in a cell using RNAi and replacing the function of the endogenous sequence with the function of an exogenous polynucleotide sequence. Also provided are methods of treatment based on the above method, and pharmaceutical composition comprising the vectors of... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC Attn: Kening Li

20080125391 - Tumor therapy with high affinity laminin receptor-targeted vectors: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to... Agent: Darby & Darby P.C.

20080125392 - Glycolipids: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection is also described.... Agent: Townsend And Townsend And Crew, LLP

20080125393 - Methods of selectively treating diseases with specific glycosaminoglycan polymers: The present invention demonstrates that defined, specific GAG molecules have discerned differential effects, and that different types of cancers are prevented from proliferating and/or killed by oligosaccharides of different sizes; one size sugar does not treat all cancers effectively. Likewise, certain size GAGs have more potent angiogenic properties; thus, mixtures... Agent: Dunlap Codding & Rogers, P.C.

20080125394 - Oral compositions for absorption of phosphorus compounds: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from... Agent: Nixon & Vanderhye, PC

20080125395 - Compositions and methods for the treatment of skin: An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at... Agent: Wilson Sonsini Goodrich & Rosati

20080125396 - Derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators: The present invention relates to certain novel compounds of formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory... Agent: Pepper Hamilton LLP

20080125397 - 2 (sulfonyl)ethyl n,n,n',n' tetrakis(2 chloroethyl)phosphorodia: 2-({2-Oxo-2-[(pyridin-3-ylmethyl)amino]ethyl}sulfonyl)ethyl N,N,N′,N′-tetrakis(2-chloroethyl)phosphorodiamidate and its acid addition salts, especially in solid form, their preparation and intermediates in their preparation, formulations containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.... Agent: Foley & Lardner LLP

20080125398 - 2-ethyl n,n,n',n'-tetrakis(2-chloroethyl)phosphorodiamidates: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N′,N′-tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.... Agent: Foley & Lardner LLP

20080125367 - Agents for treatment of hcv and methods of use: An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080125399 - 17 beta-acetamide-4-azasteroids as androgen receptor modulators: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20080125400 - Use of phosphoenolpyruvate derivatives: or a physiologically acceptable salt thereof is administered to a patient to reduce or inhibit necrosis of cardiac muscle tissue as evidenced by a reduction in the levels of cardiac troponins in the blood. A particularly preferred derivative is phosphoenolpyruvic amide (“PEPA”), i.e. wherein X═O; Y═NH2; and Z1=Z2=OH.... Agent: Conley Rose, P.C. David A. Rose

20080125402 - Methods of hormonal treatment utilizing ascending-dose extended cycle regimens: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080125401 - Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido: e

20080125405 - Composition for treating or preventing olfactory disorder: Disclosed is a composition for treating olfactory disorders, the composition comprising at least one statin-like drug, which is an HMG-CoA reductase inhibitor, as an active ingredient. The composition has excellent effects of protecting and regenerating olfactory nerve.... Agent: Edwards Angell Palmer & Dodge LLP

20080125403 - Method of treating men with metabolic and anthropometric disorders: A method of safely and specifically treating the combined metabolic disturbances of insulin resistance and visceral adiposity in male subject with visceral adiposity, metabolic syndrome (also known as the ‘insulin resistance syndrome’, and ‘syndrome X’), type II diabetes, or insulin resistance by administering a 5-alpha reductase inhibiting compound of structural... Agent: Merck And Co., Inc

20080125404 - Purine and pyrimidine cdk inhitbitors and their use for the treatment of autoimmune diseases: The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof... Agent: Lahive & Cockfield, LLP

20080125406 - Method for treating primary and secondary forms of glaucoma: Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred... Agent: Alcon

20080125407 - Method for preparation of fluticasone propionate: Taught is a method for preparing S-fluoromethyl-6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate (fluticasone propionate). The present method is simple, convenient, and mild, yields highly pure product, and is suitable for use commercially on a large scale.... Agent: Matthias Scholl

20080125408 - Penem prodrug: u

20080125409 - 1,5-diheterocycle-1h-triazole derivative:

20080125410 - 1h-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use:

20080125411 - Dispiro 1,2,4-trioxolane antimalarials: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the... Agent: Mckee, Voorhees & Sease, P.L.C

20080125412 - Polyarylcarboxamides useful as lipid lowering agents: m

20080125413 - Cgrp receptor antagonists: Compounds of Formula I: (where variables R1, R2, R3, R7, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache,... Agent: Merck And Co., Inc

20080125414 - Method of treatment: m

20080125415 - Novel methods for treatment of diseases related to activated lymphocytes: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080125418 - Benzimidazole derivatives and their use as kdr kinase protein inhibitors: wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080125417 - Certain pyrimidines, method of making, and method of use thereof: e

20080125416 - Sigma receptor inhibitors: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.... Agent: Morgan & Finnegan, L.L.P.

20080125419 - Benzothiazole derivatives with activity as adenosine receptor ligands: The present invention relates to substituted benzothiazole derivatives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080125420 - Synergistic insecticidal compositions: e

20080125421 - Synergistic insecticidal compositions:

20080125422 - Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions: The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080125423 - Fab i inhibitors: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.... Agent: Goodwin Procter LLP Patent Administrator

20080125424 - Derivatives of urea and related diamines, methods for their manufacture, and uses therefor: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.... Agent: Amgen Inc.

20080125426 - Novel compounds: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080125425 - Pyrrolo[3,2-d] pyrimidines that are selective antagonists of a2badenosine receptors: e

20080125429 - Aryloxy-substituted benzimidazole derivatives: [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with... Agent: Merck And Co., Inc

20080125428 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional EGFR and/or erbB-2 inhibitor. In particular, the method relates to methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080125427 - Novel inhibitors of rho-kinases: Novel inhibitors of Rho-kinases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080125430 - New small molecule inhibitors of mdm2 and the uses thereof: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).... Agent: Casimir Jones, S.c.

20080125431 - Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the... Agent: Birch, Stewart, Kolasch & Birch, LLP

20080125432 - 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family: wherein X, Y1, Y2, R1, n, R3, R8, R9, R10, L1, L2, Ar1 and Ar2 are defined in claim 1. The invention also relates to methods for preparing said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods for treatment of the human... Agent: Wolf Greenfield & Sacks, P.C.

20080125433 - Method of treating hair loss using thyromimetic compounds: The present invention provides methods and compositions for treating hair loss, including arresting and/or reversing hair loss and/or promoting hair growth, in mammals, such as humans, companion animals and livestock, using certain thyromimetic compounds.... Agent: Pfizer Inc.

20080125434 - Heterocyclic derivatives and their use as strearoyl-coa desaturase inhibitors: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8... Agent: Seed Intellectual Property Law Group PLLC

20080125435 - 1-(het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the ep2 receptor: The present invention relates to aryl-3-[(het)aryl-piperidin-4-yl]-thioureas, processes for the production thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are connected with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20080125436 - Mglur5 modulators: e

20080125438 - Allosteric modulators of the a1 adenosine receptor: wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula... Agent: Christopher A. Klein King Pharmaceuticals, Inc.

20080125437 - Mapk/erk kinase inhibitors: e

20080125439 - Diazaindole-dicarbonyl-piperazinyl antiviral agents:

20080125440 - Tyrosine kinase inhibitors containing a zinc binding moiety: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080125441 - Spiro and dispiro 1,2,4-trioxolane antimalarials: A means and method for treating malaria, schistosomiasis, and cancer using a Spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted... Agent: Mckee, Voorhees & Sease, P.L.C

20080125442 - Cathepsin k inhibitors and atherosclerosis: This invention relates to a genus of compounds, represented by the formula (I) diagrammed below, wherein the meanings of R1, R2, R3, R4, R5, R6, R7, R8, D and n are indicated therein, which are inhibitors of cathepsin K. These compounds are useful for treating or preventing atherosclerosis and atherosclerotic... Agent: Merck And Co., Inc

20080125443 - Cardioprotective delta opioid receptor agonists and methods of using same: The present invention relates to compositions and methods of treatment for cardioprotection through the use of non-peptidic delta opioid receptor agonist compound(s) that mediate cardioprotective effects of ischemic preconditioning. The compounds are used to reduce injury associated with ischemia and reperfusion of cardiac tissue. Further, the compounds may be used... Agent: Moore & Van Allen PLLC

20080125444 - Acyclic oximyl hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080125445 - 5,6-dialkyl-7-amino-azolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds: i

20080125446 - Purine analogs having hsp90-inhibiting activity: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080125447 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20080125448 - Quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.... Agent: Elmore Patent Law Group, PC

20080125449 - Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers: The present invention is directed in part towards methods of modulating the function of calcium channels with pyrimidine-based compounds. In addition, the invention describes methods of preventing and treating calcium channel-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to pyrimidine-based compounds and... Agent: Knobbe Martens Olson & Bear LLP

20080125450 - Pharmaceutical compositions comprising a camptothecin derivate: The present invention relates to novel pharmaceutical compositions in which the active agent is a topoisomerase I inhibitor, in particular a camptothecin derivative, that is useful for the treatment and prevention of proliferative diseases including cancer.... Agent: Novartis Corporate Intellectual Property

20080125451 - Vinorelbine derivatives: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20080125452 - Indolopyridines,benzofuranopyridines and benzothienopyridines: e

20080125453 - Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions: Compositions of tannate salts of phenylephrine, pyrilamine, and dextromethorphan produced by a method that allows for the in-situ conversions and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving salts of phenylephrine, pyrilamine, and dextromethorphan in a solvent and mixing with a dispersing agent... Agent: Moore & Van Allen PLLC

20080125455 - Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands: A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile,... Agent: Foley And Lardner LLP Suite 500

20080125454 - Methods and compositions for treatment of scleritis and related disorders: c

20080125456 - Injection of tacrolimus: This invention relates to tacrolimus injection comprising tacrolimus as an active ingredient, macrogol 15 hydroxystearate as a surfactant and a non-aqueous solvent.... Agent: Sughrue Mion, PLLC

20080125457 - O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080125459 - N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof: e

20080125458 - Novel crystalline form of cyano-1-cyclopropyl-7-1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid: The present invention relates to the trihydrate of pradofloxacin, to a process for its preparation and to antibacterial compositions comprising them.... Agent: Bayer Healthcare LLC

20080125460 - Imidazopyridine-derivatives as inducible no-synthase inhibitors: e

20080125461 - (r,r)-formoterol in combination with other pharmacological agents: This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using stereomerically pure (R,R)-formoterol in combination with other pharmacological agents such as leukotriene inhibitors and neurokinin receptor antagonists. Pharmaceutical compositions comprising (R,R)-formoterol and other pharmacological agents are also disclosed.... Agent: Jones Day

20080125462 - Cinnamate salts of a beta-2 adrenergic agonist: This invention relates to cinnamate salts of 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080125463 - N-(1-hetarylpiperidin-4-yl)(het)arylamides as ep2 receptor modulators: The present invention relates to (het)aryl-3-[(het)arylpiperidin-4-yl]amides, to processes for their preparation and to their use for producing pharmaceutical compositions for treatment of disorders and indications connected to the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20080125464 - Prucalopride n-oxide: The present invention is concerned with a novel benzamide derivative and the pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions comprising said novel compound, processes for preparing said compounds and compositions, and the use thereof as a medicine in the treatment of gastrointestinal motility disorders.... Agent: Philip S. Johnson Johnson & Johnson

20080125465 - Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene... Agent: Intrexon Corporation

20080125466 - Aryl-substituted benzo[d]isothiazol-3-ylamine analogues: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edwards Angell Palmer & Dodge LLP

20080125467 - Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.... Agent: Morrison & Foerster LLP

20080125468 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using... Agent: Eli Lilly & Company

20080125469 - Thiadiazole compounds and methods of use thereof: The present invention relates to Thiadiazole Compounds; compositions comprising an effective dose of a Thiadiazole Compound; and methods treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface... Agent: Wilmerhale/wyeth

20080125470 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Fish & Richardson PC

20080125471 - Water-soluble tetrazolium salts: Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkylammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings attached to the tetrazolium ring. Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkyl ammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings... Agent: Nixon Peabody LLP

20080125472 - Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure: The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080125473 - Substituted imidazoles: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20080125474 - Pyrazole analogs: or a pharmaceutically acceptable salt and solvate thereof, wherein R1 is F or H and to processes for the preparation of, intermediates used in the preparation of, compositions containing the uses of, such compounds. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in... Agent: Pfizer Inc.

20080125475 - Mixed orl1/mu-agonists for the treatment of pain: The invention relates to the use of compounds which exhibit an affinity for the μ-opioid receptor of at least 100 nM (Ki value, human) and an affinity for the ORL-1 receptor, wherein the ratio between the affinities ORL1/μ defined as 1/[Ki(ORL1)/Ki(μ)] is from 0.1 to 30, for the treatment of... Agent: Norris, Mclaughlin & Marcus, Pa

20080125476 - Carvedilol phosphate: The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof.... Agent: Kenyon & Kenyon LLP

20080125477 - 7-(acryloyl) indole compositions and methods of making and using same: e

20080125478 - Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080125479 - Wortmannin analogs and methods of using same: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well, as tumor formation in a subject are described herein.... Agent: Pepper Hamilton LLP

20080125480 - Oil-in-water formulation of avermectins: Oil-in-water emulsion formulations (EW) of avermectins based on phthalates as organic solvent and the use of such formulations for the control of pests.... Agent: Jacobson Holman PLLC

20080125481 - Isoflavone metabolites: l

20080125482 - Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves... Agent: Goudreau Gage Dubuc

20080125483 - Gaba analogs, compositions and methods for manufacturing thereof: The invention provides novel compounds of Formula (I), pharmaceutical compositions and methods of synthesis thereof.... Agent: Winston & Strawn LLP Patent Department

20080125484 - Synthetic lactone formulations and methods of use: Natural and synthetic compounds having a lactone structure methods for using and making the compounds have been disclosed. The compounds are useful as anti-bacterial, anti-fungal and anti-inflammatory agents, and for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080125486 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ: The present invention refers to the use of the compound of Formula (I′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates... Agent: Frommer Lawrence & Haug

20080125485 - Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or phrophylactic treatment of, inter alia, actinic keratosis.... Agent: Frommer Lawrence & Haug

20080125487 - Elongase gene and uses thereof: The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “Δ9-elongase”) and to uses thereof. In particular, Δ9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20080125488 - Lactate containing pharmaceutical composition and uses thereof: The invention relates to a pharmaceutical composition containing 250 to 2400 millimoles per liter of lactate or lactic acid, 2 to 10 millimoles per liter of potassium cation and optionally 2 to 5 millimoles per liter of calcium cation. The invention also relates to pharmaceutical uses of this composition. The... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080125489 - Methods and compositions for the treatment and prevention of lung disease: Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080125490 - Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering omega-3 fatty acids: Compositions comprising omega-3 fatty acids are provided, where the compositions are useful for treating cardiovascular disease in patients suffering from chronic kidney disease (CKD), preventing its further progression, and treating underlying risk factors such as hypertension, dyslipidemia, obesity and/or diabetes. Also provided are methods of using the compositions to reduce... Agent: Arent Fox LLP

20080125491 - Human g protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells. In certain embodiments, the GPCR is neuroprotective or... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20080125492 - Medicaments containing panthenol: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.... Agent: Fish & Richardson PC

20080125493 - Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of periventricular leukomalacia.... Agent: The Firm Of Hueschen And Sage

20080125494 - Alkylamine as an antimicrobial agent in ophthalmic compositions: where R1 is a C13-17 alkylamine, and R2 and R3 are each independently H or —CH3, and a non-ionic surfactant. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity inducing component, a surfactant, taurine, propylene glycol and/or a tonicity component. This solution additionally prevents losses... Agent: Advanced Medical Optics, Inc.

20080125495 - Ameliorant for renal insufficiency: e

20080125496 - Antimicrobial flavor and oral care composition containing the same: The present invention provides antimicrobial flavors and flavor compositions which are of high safety and little influential on intestinal bacteria, as well as oral care compositions and foods containing the same. The flavor is selected from dihydrofarnesol, isocamphylcyclohexanol, levosandol, bacdanol, Santalinol, methyl atrarate, 10-undecen-1-ol, 2-methyl undecanal, sandalol, dodecanal, brahmanol, neroridol,... Agent: Sughrue Mion, PLLC

20080125497 - Tagetes erecta marigolds with altered carotenoid compositions and ratios: A marigold plant, a regenerable portion thereof and seed are disclosed whose flower petals, leaves or flower petals and leaves contain one or more of an enhanced neoxanthin plus violaxanthin ratio, an enhanced β-carotene ratio, an enhanced lycopene ratio, an enhanced α-cryptoxanthin ratio, an enhanced phytoene ratio or an enhanced... Agent: Welsh & Katz, Ltd

20080125498 - Treatment of neurodegenerative diseases and conditions using par1 antagonists: The present invention features methods for treating and/or preventing neurodegenerative and/or neurotoxic diseases, conditions, and injuries, by inhibiting the activity of protease-activated receptor-1 (PAR1) on neurons and glial cells using PAR1 antagonists.... Agent: Needle & Rosenberg, P.C.

20080119387 - Compositions and methods for regulating peptidyltransferase activity and uses thereof: The present invention provides compositions and means to identify compositions that increase −1 PRF programmed ribosomal frameshift (−1PRF) efficiencies and/or decrease peptidyltransferase activity in a cell, and thus directly affect viral replication or assembly of viral particles. Compositions identified in accordance with the invention specifically inhibit the interaction between ribosomal... Agent: Elmore Patent Law Group, Pc

20080119389 - Compositions comprising epigallocatechin gallate and protein hydrolysate: The present invention describes a composition comprising EGCG and a protein hydrolysate.... Agent: Nixon & Vanderhye, Pc

20080119388 - Methods of using sip-10 to assess hcv clearance and/or response to interferon therapy: The present invention relates to methods for evaluating and predicting clinical outcomes in patients by measuring levels of sIP-10 protein expression as well as therapies using sIP-10 and its fragments.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119385 - Modified two-component gelation systems, methods of use and methods of manufacture: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components... Agent: Blakely Sokoloff Taylor & Zafman

20080119386 - Nutritional formula for athletes' recovery: A nutritional composition for athletes comprising in combination components for reducing oxidative stress, components for energy production and for maintaining lean muscle, the key component of which is SOD/gliadin.... Agent: Schweitzer Cornman Gross & Bondell LLP

20080119390 - Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus: Synthetic peptides of at least 12 and at most 30 amino acid residues comprising a sequence consisting of, or found within, a complementarity-determining region (CDR) found in the heavy or light chain of the human anti-DNA 16/6Id monoclonal antibody, or a sequence obtained by replacement and/or deletion and/or addition of... Agent: John P. White Cooper & Dunham LLP

20080119384 - Use of tpo peptide compounds and pharmaceutical compostions in the treatment of anemia: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20080119392 - Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.... Agent: Jones Day

20080119393 - Novel exendin agonist compounds: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080119394 - Unitary combinations of fsh and hcg: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the... Agent: Foley And Lardner LLP Suite 500

20080119396 - Tgf derepressors and uses related thereto: The application is directed to TGF analogs/derepressors that bind to and neutralize cystine knot-containing BMP antagonists—such as the CAN subfamily of Cystine-knot proteins including sclerostin. The subject TGF derepressors can be prepared as substantially pyrogen-free pharmaceutical compositions for administration to mammals, in treating diseases such as bone diseases including osteoporosis,... Agent: Ropes & Gray LLP

20080119401 - Analogs of parathyroid hormone: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate... Agent: Biomeasure, Incorporated

20080119404 - Antiobesity drug: An antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent comprising an angiopoietin-related growth factor (AGF) or a polynucleotide encoding the same as an active ingredient a polypeptide are disclosed. Further, a functional food or a health food for alleviating obesity, diabetes, and/or hyperlipemia, comprising the AGF as an active... Agent: Sughrue Mion, Pllc

20080119402 - Compositions and methods for the inhibition of dishevelled proteins: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ... Agent: Enzo Biochem, Inc.

20080119399 - Epidermal growth factor receptor-derived peptides: e

20080119405 - Fowlicidins and methods of their use: Antimicrobial peptides and methods for their use are provided. The peptides are optimized, truncated versions of chicken cathelicidins (“fowlicidins”).... Agent: Fellers Snider Blankenship Bailey & Tippens

20080119403 - Haparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same: A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080119409 - Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol): The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080119398 - Modified thioredoxin: ABSTRACT The present invention relates to a human modified thioredoxin composed of any of the following polypeptides:(a) a polypeptide modified by alteration or chemical modification of a cysteine residue at position 35 with another amino acid in an amino acid sequence of SEQ ID NO:2; and (b) a polypeptide having... Agent: Knobbe Martens Olson & Bear LLP

20080119400 - Modified truncated complement system regulators: Analogs of regulators of complement activation (RCA) proteins which have altered specificities and affinities for the targets C3b and/or C4b are described. These analogs are obtained by substituting amino acids which affect the complement inhibitory activities of these proteins, substituting, rearranging or adding SCRs (short consensus repeats) or SCR regions... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080119410 - Modulation of pericyte proliferation: Methods and materials for modulating pericyte and epithelial cell proliferation relating to BPI protein products or inhibitors thereof are provided.... Agent: Anne Dollard Xoma (us) Llc

20080119406 - Osteoblast growth factor: The present invention provides to the isolation of a small cysteine rich secretory protein from a haematopoietic macrophage cell line, which is capable of elevating cytosolic calcium levels. In particular, the present invention provides a method of treating or preventing bone disorders or diseases comprising the step of administering a... Agent: Duane Morris, LLP Ip Department

20080119408 - Pth formulations for intranasal delivery: What is described is an aqueous pharmaceutical formulation for intranasal delivery of PTH, consisting essentially of PTH(1-34) and sorbitol; or PTH(1-34), sorbitol, and a surface active agent; or PTH(1-34), sorbitol, and halogenated alkyl alcohol; or PTH(1-34), sorbitol, a surface active agent, and a halogenated alkyl alcohol.... Agent: Nastech Pharmaceutical Company Inc

20080119407 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R′, RP, RP3, LP1, LP2, ZP, RB, RB′, LXB and ZXB are as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.... Agent: Eli Lilly & Company

20080119412 - Polypeptides for modulating binding of trp channel proteins and trp- associated proteins: This invention relates to inhibitors and modulators of the binding between a transcient receptor potential (TRP) channel protein and a TRP-associated binding protein. In particular inhibitors and modulators of the binding between the TRPM7 channel protein and PDZ-domain containing TRP-associated proteins. These modulators and inhibitors are used to control Ca2+... Agent: Townsend And Townsend And Crew, LLP

20080119413 - Low density cosmetic formulations, cosmetic products containing the same and methods of treating hair, nails and/or skin using the same: Low density cosmetic formulations which comprise: (a) a cosmetic mixture; and (b) a gas incorporated in the cosmetic mixture; wherein the cosmetic mixture comprises (i) an alk(en)ylpolyglycoside, (ii) a quaternary ammonium polymer, and (iii) a thickener, are described along with suitable cosmetic mixtures for forming such low density formulations, methods... Agent: Connolly Bove Lodge & Hutz LLP

20080119414 - Mixtures of quaternary and non-ionic surfactants: wherein, R2 is a linear or branched alkyl and/or alkenyl group containing 4 to 22 carbon atoms, G is a sugar unit containing 5 or 6 carbon atoms, x is a number of 1 to 10, y is a number of 1 to 4 and Z is an —OCH2—(CH(B))v—(CH(A))w-N+(R3R4R5)X− group,... Agent: Cognis Corporation Patent Department

20080119415 - Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.... Agent: Townsend And Townsend And Crew, LLP

20080119416 - New steroids having increased water solubility and resistance against metabolism, and methods for their production: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of... Agent: Morrison & Foerster LLP

20080119417 - Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same: A metabolic syndrome relieving agent that is free from a problem of side effects and can be taken for a long term is provided. Aurapten is used as an agent for relieving a metabolic syndrome. Since aurapten has functions of activating PPARα and PPARγ, promoting the secretion of adiponectin in... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080119418 - C-9 alkenylidine bridged macrolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, Pc

20080119420 - Saponins derived from ilex pubescens and method of purifying the same: Two hitherto unreported novel triterpene saponins were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of the triterpene saponin fraction have been elucidated to possess anti-inflammatory and analgesic activity. These two novel triterpene saponins and the triterpene saponin fraction may be... Agent: Eagle Ip Limited

20080119421 - Process for treating a biological organism: A process for treating a biological organism, comprising the steps in which a cell cycle arresting drug is administered to the organism to produce synchronized cells, the microtubules within the synchronized cells are stabilized by means of a microtubule stabilizing agent, and the synchronized cells with the stabilized microtubules are... Agent: Buchanan Ingersoll Pc Including Attorneys From Burns, Doane,

20080119422 - Indole derivatives: p

20080119425 - Clusterin antisense therapy for treatment of cancer: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering... Agent: Marina Larson & Associates, Llc

20080119424 - Combined use of prame inhibitors and hdac inhibitors: The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from... Agent: Nixon & Vanderhye, Pc

20080119430 - Compositions and methods for angiogenesis-related molecules and treatments: Short interfering RNA (siRNA) molecules which modulate the expression of an angiogenesis-related gene by RNA interference are described. Short hairpin RNA (shRNA) molecules comprising said siRNA molecules are also described. These molecules can target all, or specific, isoforms of the gene. The use of these molecules and of isoforms of... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080119433 - Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance: Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as... Agent: Kilpatrick Stockton LLP

20080119426 - Compositions and methods for the treatment of muscle wasting: The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the... Agent: Patent Docket Administrator Lowenstein Sandler Pc

20080119427 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides douse stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif,... Agent: Woodcock Washburn LLP

20080119435 - Hes6 as a marker of pancreatic endocrine cells: The present invention provides methods of identifying endocrine stem and progenitor cells.... Agent: Townsend And Townsend And Crew, LLP

20080119432 - Inhibition of metallo-beta-lactamase by rna: Compositions and methods for identifying polyribonucleotides that binds with high affinity to a metallo-β-lactamase. The polyribonucleotides inhibit the activity of the metallo-β-lactamase.... Agent: Jackson Walker LLP

20080119428 - Method for diagnosing non-small cell lung cancers by trna-dihydrouridine synthase activity of urlc8: The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for... Agent: Townsend And Townsend And Crew, LLP

20080119423 - Methods and materials for modulating p2x2: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of P2X2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding P2X2.... Agent: Fish & Richardson P.c.

20080119429 - Methods and means for increasing resistance to cell damage: Methods are provided to increase resistance to cell damage in a subject. The increase in resistance to cell damage in a subject in the subject is accomplished by decreasing activity of eEF2 kinase in the subject. The eEF2 kinase activity can be decreased by decreasing the amount of functional eEF2... Agent: Synnestvedt Lechner & Woodbridge LLP

20080119431 - Per-6-guanidino-, alkylamino-cyclodextrins, methods of their synthesis and their use for the compaction of dna and interacellular delivery: The invention relates to new compounds of type hexakis(6-deoxy-6-NH(CH2)n, —R1)α-cyclodextrin and heptakis(6-deoxy-6-NH(CH2)n—R1)-(β-cyclodextrin, and octakis(6-deoxy-6-NH(CH2)n—R1)-γ-cyclodextrin, where n=2-6 when R1═NH2 and n=0 when R1═C(═NH)NH2 and n=2-6 when R1═NH—C(═NH)NH2 and their use in the compaction of DNA and in cell permeation. The invention also relates to methods of synthesis of the above compounds.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20080119436 - Regulation of oncogenes by micrornas: Naturally occurring miRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080119434 - Sir2a-based therapeutic and prophylactic methods: This invention provides methods for treating and for inhibiting the onset of cancer in a subject comprising administering an agent that inhibits the ability of Sir2α to inhibit p53-dependent apoptosis. This invention also provides a related method for inducing the death of a cell. This invention further provides a method... Agent: John P. White Cooper & Dunham, LLP

20080119438 - Heparin compositions that inhibit clot associated coagulation factors: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to... Agent: Millen, White, Zelano & Branigan, P.c.

20080119440 - Combination with bis(thiohydrazide amides) for treating cancer: Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080119439 - Treatment and prevention of intestinal fibrosis: The present invention is directed to the use of lipoxin A4 analogs as therapeutic agents in the treatment and/or prevention of intestinal fibrosis.... Agent: Jacqueline S Larson

20080119442 - Nitrobenzindoles and their use in cancer therapy: The present invention relates generally to nitro-1,2-dihydro-3H-benzo[e]indoles and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.... Agent: Nixon & Vanderhye, Pc

20080119441 - Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia: [wherein: A is selected from —(CH2)n—, —CO—, —(CH2)n—CO—(CH2)m—, —(CH2)n—CS—(CH2)m— or branched alkylene group. B ring and C ring are selected from benzene ring, naphthalene ring, azulene ring or, heterocycle or fused heterocycle. D is —(CH2)(n+1)—, —(CH2)-O—(CH2)m—, —(CH2)—S(O)o—(CH2)m—, —CF3 or —(CH2)n—NR10—(CH2)m— (wherein: D ring is connected with the carbon atom composing... Agent: Flynn Thiel Boutell & Tanis, P.c.

20080119391 - Method for treating wounds to promote healing: A method of treating a mammal to promote wound healing in the mammal in need thereof, comprising orally administering to the mammal an effective amount of a palatable, concentrated protein composition comprising an effective amount of hydrolyzed gelatin and tryptophan, and an ingestible carrier, the composition comprising the essential amino... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080119395 - Novel depsipeptides and process for preparing same: The present invention relates to novel depsipeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel depsipeptide compounds and intermediates used in producing these compounds.... Agent: Intellectual Property Department Cubist Pharmaceuticals, Inc.

20080119397 - Kahalalide compositions: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.... Agent: King & Spalding

20080119411 - Orally administering parathyroid hormone and calcitonin: A method for orally administering a parathyroid hormone, PTH, comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of calcitonin. The method according to the invention allows for the oral administration of PTH without the hypercalcemia, hypercalcuria and nephrolithiasis... Agent: Novartis Corporate Intellectual Property

20080119419 - Bifunctional heterocyclic compounds and methods of making and using same: The invention provides a family of bifunctional heterocyclic compounds useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The invention also provides methods of making the bifunctional heterocyclic compounds, and methods of using such compounds as anti-infective, anti-proliferative agents, anti-inflammatory, and/or prokinetic agents.... Agent: Testa, Hurwitz & Thibeault, LLP

20080119437 - Hyaluronate compositions: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for malting and using the same.... Agent: Choate, Hall & Stewart LLP

20080119443 - Certain lithocholic acid analogues that inhibit sialyltransferase: and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof are described. Pharmaceutical compositions comprising at least one chemical entity chosen from compounds of Formula I and a pharmaceutically acceptable vehicle are described. Also described are methods for inhibiting α-2,3-sialyltransferase activity in cells, and methods for treating a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080119444 - Methods and compositions for the treatment of cancer: The present invention provides methods to treat neoplastic disorders in a human comprising the use of aromatase inhibitors and HMG-CoA reductase inhibitors (statins).... Agent: Dann, Dorfman, Herrell & Skillman

20080119445 - Methods of female sexual enhancement: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and... Agent: Michael A. O'neil Michael A. O'neil, P.c.

20080119447 - 6-alkoxyalkyl estradiol derivatives and methods of use: wherein R1, R2, R3, R4, R5, R6, R7 and R9 are independently hydrogen, C1 to C6 alkyl or substituted alkyl, halogen, sulfate or glucuronide moieties; the symbol represents either a single or a double bond and when the symbol is a double bond and forms a keto group... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20080119446 - Prodrugs for use as ophthalmic agents: The subject invention provides a mechanism by which steroidal quinol compounds confer beneficial ophthalmic effects. The subject compounds possess a lipophilic-hydrophilic balance for transcorneal penetration and are readily reduced into parent phenolic A-ring steroid compounds to provide protection or treatment against various ocular symptoms and disorders. The compounds according to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080119448 - Methods of treating an ocular allergy with low dose dexamethasone: The present invention is directed to a method of treating an ocular allergy with a composition comprising a low dose of dexamethasone. In some embodiments, the present invention is directed to a method of treating an ocular allergy, the method comprising administering to an ocular surface of a subject in... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080119449 - Methods for treating postmenopausal women using ultra-low doses of estrogen: The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present... Agent: Townsend And Townsend And Crew, LLP

20080119450 - Use of creatine or creatine analogs for the treatment of diseases of the nervous system: The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and... Agent: Lahive & Cockfield, LLP

20080119451 - Novel benzamide derivatives: The invention concerns benzamide derivatives of Formula (I) wherein R1a, R1b, R1c, R2, R3, R4, integer m, integer n and W have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as... Agent: Astrazeneca R&d Boston

20080119452 - Methods for enhancing cognitive function: Methods for enhancing cognitive function are disclosed. More particularly, methods are disclosed for enhancing cognitive function comprising the step of administering spirocyclic heterocyclic derivatives (including derivatives of spiro(2H-1-benzopyran-2,4′-piperidines) of the general formula IV:... Agent: Woodcock Washburn LLP

20080119453 - Bicyclic derivatives as modulators of ion channels: The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080119457 - Benzene, pyridine, and pyridazine derivatives: wherein A, Q1, Q2, Q3, R31, and R41 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080119456 - Substituted thiazoleacetic acid as crth2 ligands: Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X1 is —S—, —O—, —N═N—. —NR7—, —CR7═CR8—, —CR7═N—, wherein R7 and R8 are independently hydrogen or C1-C3 alkyl; A is a... Agent: Banner & Witcoff, Ltd.

20080119458 - N-substituted-azacyclylamines as histamine-3 antagonists: m

20080119454 - Aryl carbonyl derivatives as therapeutic agents: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.... Agent: Novo Nordisk, Inc. Patent Department

20080119455 - Aryl carbonyl derivatives as therapeutic agents: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.... Agent: Novo Nordisk, Inc. Patent Department

20080119459 - Trifluoromethylbenzamide derivatives and therapeutic uses thereof: Compounds of the formula (I), in which the radicals R1 to R3 and AR are as defined in the description, processes for the preparation thereof, the use thereof in the treatment of cardiovascular diseases, and pharmaceutical compositions comprising them.... Agent: Millen, White, Zelano & Branigan, P.c.

20080119460 - Allosteric modulators of the a1 adenosine receptor: wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula... Agent: Christopher A. Klein King Pharmaceuticals, Inc.

20080119461 - Hepatitis c virus inhibitors: e

20080119462 - Method for treating vascular hyperpermeable disease: The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119463 - 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml): The claimed invention is directed to a method of treating, inhibiting, or preventing acute myelogenous leukemia, also called acute myeloid leukemia (AML), using 4-anilino-3-quinolinecarbonitriles.... Agent: Wyeth Patent Law Group

20080119464 - Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv): e

20080119465 - Novel indoline compounds:

20080119466 - Heteroarylphenylurea derivative:

20080119468 - Phthalazine, aza-and diaza-phthalazine compounds and methods of use: wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates... Agent: Amgen Inc.

20080119467 - Purine derivatives, compositions containing them and use thereof: Purine derivatives of formula (IA1) or (IB1), compositions containing them and use thereof as medicinal products, in particular in oncology, are described... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080119469 - Novel compounds: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080119470 - Neurologically-active compounds: Neurologically-active heterocyclic compounds comprising two fused 6-membered rings with nitrogen atoms at positions 1 and 3, a carboxy group at position 4, and a hydroxy group at position 8, with one ring being aromatic. Processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in... Agent: Scully, Scott, Murphy & Presser, P.c.

20080119471 - Piperazine urea derivatives for the treatment of endometriosis: u

20080119473 - Compounds for nonsense suppression, and methods for their use: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a... Agent: Hoffmann & Baron, LLP

20080119472 - Solid biocide formulations: Abstract Biocidal compositions that contain biocidal components, such as an oxidant, and mixed with said components a combination of inorganic compounds capable of reducing the oxidative capacity of the biocidal components by forming a low-melting glass when heated. The biocidal composition may be heated by being ignited or subjected to... Agent: Kevin D Mccarthy Roach Brown Mccarthy & Gruber

20080119474 - Novel pyridazine derivatives and medicines containing the same as effective ingredients: wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (substituted) aryl group, a (substituted) aryloxy group, a (substituted)... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119475 - Conjugates and use thereof: e

20080119476 - Cetp inhibitors: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring... Agent: Merck And Co., Inc

20080119477 - N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto: The present invention relates to certain biarylz and arylheteroaryl piperazine derivatives of Formula (Ia) that are modulators of the 5HT2c receptor. Accordingly, compounds of the present invention are useful for the treatment of 5HT2c receptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.... Agent: Fish & Richardson P.c.

20080119478 - 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis: The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and —(CH2)nR2 may form a spiro ring represented by the formula (30) below,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080119479 - Combination comprising zd6474 and imatinib: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour... Agent: Morgan Lewis & Bockius LLP

20080119480 - Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Louis J. Wille Bristol-myers Squibb Company

20080119481 - Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline: The present invention relates to crystalline forms of the 5-HT1A binding agent 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline, as well as pharmaceutical compositions thereof, and methods of use thereof.... Agent: Fish & Richardson P.c.

20080119482 - Method for the treatment of attention deficit hyperactivity disorder: The invention relates to a method for the treatment of Attention Deficit Hyperactivity Disorder comprising the administration of a therapeutically effective amount of flibanserin.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080119483 - Compositions and methods for inhibiting protozoan growth: The present invention provides compositions and methods for inhibiting protozoan growth comprising a synergistic combination of lipid synthesis inhibitors. In addition, the invention provides compositions and methods that are useful for the treatment of protozoan infections and the identification of potential new drugs for the treatment of protozoan infections.... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20080119484 - Novel use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts: 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania,... Agent: Millen, White, Zelano & Branigan, P.c.

20080119485 - Novel benzofurans and indols: or a pharmaceutically acceptable salt or solvate thereof; The invention also relates to pharmaceutical compositions containing a compound of formula (I) together with a pharmaceutically acceptable carrier. Included are also processes for the preparation of compounds of formula (I), as well as methods for treating mammals suffering from inflammatory, autoimmune,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080119486 - Benzoyl-piperazine derivatives: wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080119487 - Novel non-imidazole compounds: e

20080119489 - Imidazole derivatives: wherein R1, R2, R3 and R4 are described hereinabove. These compounds can be used in the treatment or prevention of mGluR5 receptor mediated disorders. These compounds are useful, inter alia, in the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognititve disorders... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080119488 - Modulators of nuclear receptors: Compounds of the invention, such as compounds of formula (I), where n, m, A, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080119490 - Viral polymerase inhibitors: m

20080119491 - Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to amidino heterocyclic compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as to pharmaceutical compositions comprising such compounds and to pharmaceutical methods of treatment comprising administration of such compounds and pharmaceutical compositions.... Agent: Fish & Richardson Pc

20080119492 - Compositions and methods for treating cancer and other diseases characterized by abnormal cell proliferation: The present invention relates to compositions and methods for treating cancer and other disease states characterized by abnormal cell proliferation. In particular, the present invention relates to certain novel non-nucleoside pharmacologically active compounds that alter telomere and telomerase functions, regulate cell proliferation and/or treat cancer and other diseases characterized by... Agent: King & Spalding LLP

20080119493 - 5,6-dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: The invention relates to 5,6-dialkyl-7-amino-triazolopyrimidines of formula (I), in which the substituents are defined as follows: R1 represents alkyl, alkoxyalkyl, alkenyl or alkynyl; R2 represents alkyl, alkoxyalkyl, alkenyl or alkynyl, R1 and/or R2 being substituted according to the description. The invention also relates to a method for producing said compounds,... Agent: Birch Stewart Kolasch & Birch

20080119494 - Drug-enhanced adhesion prevention: The present invention includes methods for the inhibition of post-operative adhesion formation between tissue surfaces in a body cavity having been subjected to a surgical procedure, which methods involve administering Pemirolast, or an analog thereof, directly to tissue surfaces in the body cavity in amounts and under conditions effective to... Agent: Philip S. Johnson Johnson & Johnson

20080119496 - 7-substituted purine derivatives for immunosuppression: The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080119495 - Phosphodiesterase 4 inhibitors: e

20080119497 - Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones:

20080119498 - Therapeutic agent for pruritus comprising p38 map kinase inhibitor as the active ingredient: An object of the present invention is to find a novel pharmacological effect (a medicinal use) of a p38 MAP kinase inhibitor. Because of having an excellent antipruritic effect, a p38 MAP kinase inhibitor is useful as a therapeutic agent for pruritus of any types such as ocular pruritus, skin... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080119499 - Compositions havinge improved 2-photon absorbance for nonlinear applications: There are provided conjugated systems of formula (I) based on stilbene derivatives serving as improved Donor-Acceptor-Donor compounds and their use in non linear optics including chromophoric optical medium of a 3-dimensional optical memory.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080119500 - Pyridine imidazoles and aza-indoles as progesterone receptor modulators: The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as... Agent: Philip S. Johnson Johnson & Johnson

20080119501 - Immediate release oxymorphone compositions and methods of using same: The present invention relates to compositions comprising oxymorphone or a pharmaceutically acceptable salt thereof and to methods of using such compositions to treat various conditions or disorders.... Agent: Mayer Brown LLP

20080119502 - Vinca derivatives: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20080119503 - Androgen receptor modulators and methods of use thereof: Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular... Agent: Merck And Co., Inc

20080119504 - New aporphine esters and their use in therapy: New aporphine derivatives are disclosed which have formula (I) and the physiologically acceptable salts thereof. Said derivatives may be used for the treatment of Parkinson's disease, hemicrania, restless legs syndrome (RLS), sexual dysfunction in men and women, hyperprolactemia and psychotic disorders, and/or evaluation of Parkinson's disease. Processes for the preparation... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119505 - Novel 6-pyridylphenanthridines: w

20080119506 - Huperzine a and its derivatives as analgesic agents: wherein: R represents —NR1R2,—NHC(O)OR3,—N═CR4R5; Rrepresents H or C1-6alkyl; R2 represents H or C1-6alkyl; R3 represents C1-6 alkyl, a heterocyclic group or an aryl; R4 represents H,C1-6alkyl, a heterocyclic group or an aryl; and R5 represents H,C1-6 alkyl, a heterocyclic group or an aryl; or CR4R5 taken together represents a cyclolidene... Agent: Matthias Scholl

20080119507 - Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein hsp90 activities: e

20080119508 - Multi-route administration of immune response modifier compounds: A method of treating disease with immune response modifier (IRM) compounds by using at least two different routes of administration, such as administering at least one IRM to a subject locally (e.g., topically) at a disease site in combination with separately administering at least one IRM to the subject systemically... Agent: 3m Innovative Properties Company

20080119509 - Altenrative forms of the phosphodeisterase -4 inhibitor n-cyclopropyl-1- -3{3-[(1-oxidopyryidin-3-yl) phenyl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below: Compound IX... Agent: Merck And Co., Inc

20080119510 - Substituted imidazo [4,5-b] pyridines as inhibitors of gastric acid secretion: e

20080119511 - Benzo-fused compounds for use in treating metabolic disorders:

20080119512 - Carboxamide derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20080119513 - Sulfonamide derivative selectively inhibiting mmp-13: wherein Z is 1,4-phenylene and the like; R1 is hydroxy and the like; R2 is hydrogen atom, optionally substituted lower alkyl, and the like; R12 is hydrogen atom; or R2 and R12 taken together with the adjacent carbon atom may form a ring; R3 is hydrogen atom, optionally substituted lower... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080119514 - Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof: wherein X is oxygen, nitrogen or sulfur; Y is selected from the group consisting of oxygen, nitrogen and sulfur wherein when Y is oxygen or nitrogen, n is 1 and when Y is sulfur, n is 0. Also provided is a method for inducing apoptosis in a cell comprising administering... Agent: Fulbright & Jaworski, L.l.p.

20080119515 - Heterocyclic kinase inhibitors: methods of use and synthesis: Inhibitors of kinases, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making kinase inhibitor compounds, methods of inhibiting kinase activity, and methods... Agent: Palaiyur S Kalyanaraman Schering-plough Corporation

20080119516 - 2-'4(phenylamino)-piperidin-1-yl!-n-phenyl-acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity: It was an object of the present invention to provide novel compounds that are suitable in particular as active substances in medicaments, preferably in medicaments for the regulation of neuropeptide Y receptors, particularly preferably of neuropeptide Y5 (NPY5) receptor, for the regulation of food ingestion (food intake), preferably for the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119517 - Compositions and methods for protecting against mitochondria component-mediated pathology: Compositions and methods used for preventing mitochondrial component-based diseases are disclosed herein. In particular, heterocyclic compositions and methods that are directed toward protecting against changes in mitochondrial permeability transition that could result in cell death.... Agent: Burns & Levinson, LLP

20080119518 - 1-(piperidin-4- yl)-1h-indole derivatives: m

20080119519 - Base forming drug-layered silicate hybrid containing basic polymer and its synthesis method: Provided are a hybrid of a poorly soluble basic drug and a layered silicate, including a water-soluble basic polymer, and a method of preparing the same. The water-soluble basic polymer may be an aminoalkylmethacrylate copolymer (e.g., Eudragit E 100: a copolymer composed of 1:2:1 ratio of butyl methacrylate, (2,2-dimethylaminoethyl)methacrylate, and... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080119520 - Fused bicyclic-substituted amines as histamine-3 receptor ligands: o

20080119521 - Butyrlcholinesterase selective inhibitors: The invention provides butyrylcholinesterase inhibitors of formula (I), which contain an heterocyclic moiety and a 4 piperidine moiety with a linker in between. The compounds show a very high activity and selectivity towards BuChE, making them useful for the treatment and/or prophylaxis of cognitive disorders and/or neurodegenerative disorders.... Agent: Moore & Van Allen Pllc

20080119523 - 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1h-benzimidazol-5- carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament: Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080119522 - Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms): The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20080119524 - Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.... Agent: Sheridan Ross Pc

20080119525 - Pyridoxamine for the treatment of diabetic intermediaries and post-amadori inhibition: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080119526 - Ep2 receptor agonists: e

20080119527 - Composition for combating the localized hyperpigmentation of dark skin: The present invention relates to a composition comprising, in a physiologically acceptable medium, at least one copolymer of a styrene monomer and of an ethylenically unsaturated dicarboxylic acid and at least one anti-seborrhoeic active agent.... Agent: Oliff & Berridge, Plc

20080119528 - use of specific cyklolignans: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119529 - Combinations comprising epothilones and pharmaceutical uses thereof: wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable... Agent: Novartis Corporate Intellectual Property

20080119530 - Method for treatment and prevention of ultraviolet light induced skin pathologies: The present invention provides a method for suppression of ultra violet-induced skin pathologies and skin abnormalities, such as abnormal proliferation and mutagenesis, and for inducing apoptosis in cells having Erbb2 or HER2 receptors. The method involves administration of Erbb2/HER2 inhibitors, either before or after exposure to UV.... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080119531 - Indoles having anti-diabetic activity: Indoles of Formula I having —X-aryl-(CH2)x-oxazolidinedione and —X-heteroaryl-(CH2)x-oxazolidinedione substituents on the N atom of the indole ring, where x is 0 or 1, and —X— is a bond or —CH2—, and their thiazolidinedione analogs, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of... Agent: Merck And Co., Inc

20080119532 - Dimeric small molecule potentiators of apoptosis: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and... Agent: Richard Aron Osman

20080119533 - N-thiolated 2-oxazolidinone -derived antibiotics: This invention describes the discovery and synthesis of N-thiolated 2-oxazolidinones as a new class of anti bacterial agents. These compounds can be synthesized from 2-oxazolidinones by Ndeprotection and N-sulfenylation. These new substances were found to exhibit potent anti-bacterial activity, including bacteriostatic properties against Staphylococcus spp., including methicillin resistant Staphylococcus aureus... Agent: Smith Hopen, Pa

20080119534 - Benzimidazole derivatives as therapeutic agents: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20080119535 - Aminomethyl-4-imidazoles: The compound may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders,... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080119536 - Substituted imidazoles: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20080119537 - 5-aryl indan-1 one and analogs useful as progesterone receptor modulators: Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080119539 - Therapeutic amides: m

20080119538 - Therapeutic compounds:

20080119540 - Method of using oral lipase inhibitors to reduce plasma ghrelin and to prevent weight regain: The present invention comprises a method of reducing ghrelin levels in a human body for weight reduction and to permanently reduce appetite and eliminate weight regain by the step of orally ingesting tetrahydrolipstatin—THL (Orlistat) on a regular basis for a period of at least one to two years.... Agent: Donald N. Halgren

20080119542 - Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer: The invention provides methods for preventing or delaying the development of cancer by administering free radical-generating agents to a subject. Representative free radical-generating agents include endoperoxide compounds, such as endoperoxides bearing sesquiterpene compounds such as artemisinin and its analogs, arteflene and its analogs, 1,2,4-trioxanes and 1,2,4,5-tetraoxanes. Intracellular iron concentrations may... Agent: Christensen, O'connor, Johnson, Kindness, Pllc

20080119541 - Novel genes encoding a nystatin polyketide synthase and their manipulation and utility: The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 35; or (d) a nucleotide... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080119543 - Method of purifying moxidectin through crystallization: Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.... Agent: Wyeth Patent Law Group

20080119544 - Use for cannabinoid: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken... Agent: Wolf Greenfield & Sacks, P.c.

20080119545 - Method for preventing and treating avian influenza in human: A method and composition for preventing and treating Avian Influenza in Humans utilizes an effective quantity of polyphenolic(s) and/or its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3′-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3′-gallate, thearubigin, gallic acid, tannic acid,... Agent: Raymond Y. Chan

20080119546 - Treatment of hyperproliferative conditions of body surfaces: The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is a primary factor of the pathogenesis. In particular the invention relates to treatment of psoriasis,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080119547 - Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors: e

20080119548 - Control of feeding behavior by changing neuronal energy balance: Obesity is a worldwide health issue, affecting children and adults in developed and developing countries. Obesity is a disorder of both energy metabolism and appetite regulation, and may be understood as a dysfunction of energy balance. Applicants have found a means for regulating food intake by a subject by administering... Agent: Jacobson Holman Pllc

20080119549 - Metabolically-stabilized inhibitors of fatty acid amide hydrolase: Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that... Agent: Organon Usa, Inc. Patent Department

20080119550 - Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection: This invention provides hydroxybenzoic acids, their esters and analogues thereof that are useful for the prevention and/or treatment of virus infection such as HBV, papillomavirus and/or herpes virus infection.... Agent: Perkins Coie LLP

20080119551 - Skin cosmetics comprising a cystine derivative and a chemical peeling agent, a bactericide, an anionic sufactant, or a cationic surfactant: The present invention provides cosmetics or external preparations for skin are provided that contain, as the effective ingredient, a chemical peeling agent, a bactericide, an anionic surfactant or a cationic surfactant component in combination with a cystine derivative of formula (1):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119552 - Matrix-embedded compositions having organic acids and fatty acids: The invention generally provides matrix-embedded compositions having organic acids and fatty acids. The compositions may be administered to an animal to deliver intact organic acids and fatty acids to the animal's small intestine. The invention also provides monograstric feed rations comprising the matrix-embedded compositions.... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20080119553 - Activators of peroxisome proliferator-activated receptors: Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20080119554 - Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in... Agent: Fulbright & Jaworski, LLP

20080119555 - Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions: wherein: Ar1 is independently C5-20aryl (e.g., biphenyl, phenanthryl, fluorenyl, or carbazolyl, most preferably biphenyl), and is optionally substituted; RN is independently —H, acyl, C5-20aryl-C1-7alkyl, C3-20heterocyclyl, or C1-7alkyl, and is optionally substituted; Ralk is a C2-10alkylene group, and is optionally substituted; and Q is independently —H or an organic group having... Agent: Nixon & Vanderhye, Pc

20080119556 - Geranly compounds: e

20080119557 - Combination of organic compounds: (b) an angiotensin II receptor blocker (ARB), or a pharmaceutically acceptable salt thereof; for the prevention of, delay the onset of and/or treatment of a disease or a condition mediated by angiotensin II and/or NEP activity, which method comprises administering to a warm-blooded animal, in need thereof, a therapeutically effective... Agent: Novartis Corporate Intellectual Property

20080119558 - Drug for inhibiting production of matrix metalloprotease-9: A drug for inhibiting the production of matrix metalloproteinase-9 which contains leptomycin B or its derivative as the active ingredient can specifically inhibit the production of MMP-9 compared with MMP-2, furthermore, has an effect of inhibiting the production of MMP-9 even under stimulating the differentiation by adding calcium at a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119559 - Treatment or prevention of cancer and precancerous disorders: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed... Agent: Akerman Senterfitt

20080119560 - Substituted cyclopentanes or cyclopentanones as therapeutic agents: The compounds disclosed herein are useful for treating glaucoma, ocular hypertension, and baldness.... Agent: Allergan, Inc.

20080119561 - Methods for preventing or delaying catheter- based resvascularization: Aggressively lowering cholesterol in patients suffering from coronary artery disease prevents or delays the need for catheter-based revascularization.... Agent: Pfizer Inc.

20080119562 - Methods of inducing terminal differentiation: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20080119563 - Methods for rna desilylation: The invention provides tetraalkyl ammonium fluoride derivatives or a pyridine hydrogen fluoride complex to remove silyl protecting groups in oligoribonucleotides synthesis.... Agent: John Petravich Integrated Dna Technologies, Inc.

20080119564 - Levalbuterol salt: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.... Agent: Mike Crosby

20080119565 - Novel compounds from antrodia camphorata: The present invention relates to a novel compound and use thereof, in particular to Antroquinonol B and Antroquinonol C isolated from Antrodia camphorata extracts which can effectively inhibit the growth of cancer cells. The compounds from Antrodia camphorata are first reported, which can be applied not only in inhibiting growth... Agent: Rabin & Berdo, Pc

20080119566 - Hydrofluoroalkyl phenols having anesthetic properties: Substituted hydrofluoroalkylphenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20080119567 - Methods of use of herbal compositions: The present invention relates to herbal composition and methods of administering an herbal composition, comprising geranium oil and extracts from roots of the plants of the genus Sophora, particularly S. flavescenes and S. tonkinensis, to humans and other mammalian animals with gastric ulcers induced by H. pylori infection. The same... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080119568 - Gastrointestinal absorption enhancer mediated by proton-coupled transporter and its preparing method: The present invention provides a pharmaceutical preparation that can improve absorption of a pharmaceutical compound in the gastrointestinal tract and that provides, through oral administration or like method, a blood concentration from which sufficient remedial effects can be expected, and a method for producing such a preparation. The invention is... Agent: Sughrue Mion, Pllc

20080119569 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080119570 - Stable cosmetic emulsion with polyamide gelling agent: The present invention relates to a gelled cosmetic emulsion comprising an oil phase, an aqueous phase and a gelling system which contains at least one non-siloxane based polyamide in a sufficient amount to gel the emulsion. The polyamide can have an tertiary amide, ester, acid, or amine terminal end group.... Agent: The Estee Lauder Cos, Inc

20080119571 - Compositions and methods to enhance reverse cholesterol transport: The present invention shows that pharmacological up regulation of SRB-1, ABC-A1 and LCAT genes collectively can be used to promote reverse cholesterol transport and increase circulating HDL cholesterol as treatment for atherosclerosis and related cardiovascular disorders.... Agent: Reddy Us Therapeutics, Inc

20080119572 - Treatment for basal cell carcinoma: The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is... Agent: Edwards Angell Palmer & Dodge LLP

20080113896 - Blood pressure lowering peptides in a single enzymatic step: A process to produce IPP and VPP from a protein source that comprises the -I-P-P- and -V-P-P- sequence in its protein sequence and whereby at least 40% of -I-P-P- sequence present in the protein source is converted into the peptide IPP and at least 40% of the -V-P-P- sequence present... Agent: Nixon & Vanderhye, Pc

20080113898 - Methods for detecting and inhibiting angiogenesis using peptides: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the... Agent: Townsend And Townsend And Crew, LLP

20080113897 - Patent of invention p200001758,method for the transformation of chrome-free tanning waste and products thus obtained: The invention relates to improvements to patent of invention P200001758, “Method for the transformation of chrome-free tanning waste and products thus obtained”, essentially consisting in dividing the continuous process described in said patent into two sequences or subprocesses. According to the invention, during the first sequence, the industrial waste used... Agent: Sanchelima & Associates, P.a. Jesus Sanchelima, Esq.

20080113899 - Iron supplement and utilization of the same: The present inventors have found that a siderophore-iron (III) ion chelate complex is highly absorbed in the body; significantly increases the blood hemoglobin concentration, the serum iron concentration and the concentration of iron stored in the liver; and causes no adverse effects on the body. On the basis of these... Agent: Posz Law Group, Plc

20080113902 - Use of ramoplanin to treat diseases associated with the use of antibiotics: The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080113904 - Treatment of neurological conditions using complement c5a receptor modulators: This invention relates to the treatment of neurological conditions with novel cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of C5a receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes, monocytes, lymphocytes and/or macrophages.... Agent: Morrison & Foerster LLP

20080113909 - Compositions and methods for treating stat-6 associated diseases or conditions: The present invention relates to a cell permeable peptide to specifically inhibit tyrosine phosphorylation and/or subsequent activation of STAT-6. This peptide is composed of a protein transduction moiety operably linked to a portion of STAT-6 which contains tyrosine residue 641 (Tyr-641) of STAT-6, wherein Tyr-641 is phosphorylated. The chimeric STAT-6... Agent: Licata & Tyrrell P.c.

20080113912 - Formulations of human growth hormone comprising a non-naturally encoded amino acid: Formulations of modified human growth hormone polypeptides are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080113913 - Formulations of human growth hormone comprising a non-naturally encoded amino acid: Formulations of modified human growth hormone polypeptides are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080113914 - Formulations of human growth hormone comprising a non-naturally encoded amino acid: Formulations of modified human growth hormone polypeptides are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080113911 - Methods of modulating angiogenesis: The present invention provides methods of modulating angiogenesis in an individual, the methods generally involving administering to an individual an agent that modulates the expression or activity of Egfl7, where an agonist of Egfl7, including an Egfl7 polypeptide, decreases angiogenesis. In one embodiment, the methods of the invention relate to... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080113905 - Polyethylene glycol linked glp-1 compounds: The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable... Agent: Eli Lilly & Company

20080113910 - Rgd-enriched gelatine-like proteins with enhanced cell binding: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Roger Pitt Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080113906 - Sushi peptide multimer: Endotoxin, also known as lipopolysaccharides (LPS), is the major mediator of septic shock due to Gram-negative bacterial infection. Chemically synthesized S3 peptide, derived from Sushi3 domain of Factor C, which is the endotoxin-sensitive serine protease of the limulus coagulation cascade, binds and neutralizes LPS activity. Fluorescent tagged-S3 is shown to... Agent: Townsend And Townsend And Crew, LLP

20080113908 - Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases: CRF receptor agonists, especially CRF receptor-1 agonists such as CRF, urocortin, sauvagine or urotensin 1, can be used for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to chronic neurodegenerative disease (e.g. Alzheimer's disease, Parkinson's disease or Huntington's disease), traumatic (mechanical) neuronal injury,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080113907 - Uses of galectin-2: Use of galectin-2 or of a nucleic acid coding for galectin-2 or of its complementary strand, or of a nucleic acid hybridizing to such coding nucleic acid or its complementary strand, for the manufacture of a medicament for the treatment or prevention of a patient having a disease with impaired... Agent: Davidson, Davidson & Kappel, Llc

20080113917 - Tgfbeta supported and binding peptides: The present invention provides peptides and supported peptides that bind TGFβ (molecules. In some particularly preferred embodiments, the TGFβ binding molecules bind TGFβ-1, while in other embodiments, the TGFβ binding molecules bind TGFβ-2.... Agent: Kamrin T. Knight Genencor International, Inc.

20080113918 - Agonist polypeptide of receptor for zot and zonulin: Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20080113919 - Conjugated nitro alkene anticancer agents based on isoprenoid metabolism: Conjugated nitro alkene compounds hamper or prevent proliferation of cancer cells in cell culture and in cancer patients, which can result in a decrease in tumor size and/or disappearance of the cancer. The compounds may act by interference with cancer cell biochemistry, in which isoprenoid groups such as farnesyl and... Agent: Banner & Witcoff, Ltd.

20080113920 - Feed-through lignin-pesticide compositions: The present invention provides lignin-pesticide complexes, methods for making lignin-pesticide complexes, and methods for treating or controlling insect infestations on animals by administering such complexes. Advantageously, the lignin-pesticide complexes of the present invention can be used in feed-through products to control insect infestation on livestock or pets. Various insects such... Agent: Townsend And Townsend And Crew, LLP

20080113922 - Inhibitors of sodium glucose co-transporter 2 and methods of their use: Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.... Agent: Lexicon Pharmaceuticals, Inc.

20080113921 - Use of a compound comprising d-mannoheptulose and/or perseitol for treating and preventing innate immunity modification diseases: The invention relates to the use of a compound comprising D-mannoheptulose and/or perseitol for producing a drug for treating and/or preventing diseases related to the modification of an innate and/or acquired immunity by increasing the production of antimicrobial peptides, preferably hBD-2 without inducing inflammatory reactions, irritation or intolerance. Said compound... Agent: Foley And Lardner LLP Suite 500

20080113924 - Neuramindase inhibitor: e

20080113923 - Type ii cubic liquid crystal composition:

20080113925 - Compositions and methods for increasing telomerase activity: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as,... Agent: Perkins Coie LLP

20080113926 - 9a-carbamoyl-y-aminopropyl- and 9a-thiocabamoyl-y-aminopropyl-azalides with antimalarial activity: 9a-Carbamoyl-γ-aminopropyl- and 9a-thiocarbamoyl-γ-aminopropyl-azalides and their pharmaceutically acceptable derivatives are useful for treatment and prevention of malaria.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080113929 - Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist: Compositions and methods are provided for enhancing delivery of therapeutic agents. More specifically, compositions and methods are provided for improving antigen delivery to antigen-presenting cells. Conjugates between abasic oligonucleotides and antigen are provided, along with methods for their use in vaccination and in the treatment of cancer, infection, and allergy... Agent: Wolf Greenfield & Sacks, P.c.

20080113932 - Casein kinase 2 antisense therapy: The invention provides for antisense oligonucleotides that hybridize to casein kinase 2 nucleic acid sequences and methods of using such antisense oligonucleotides to inhibit expression of casein kinase 2 and reduce the size of solid tumors.... Agent: Fish & Richardson P.c.

20080113933 - Chlamydia 60 kda crmp antigens and vaccine uses: The present invention provides vaccines and methods for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a 60 kDa cysteine-rich membrane protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of... Agent: Smart & Biggar P.o. Box 2999, Station D

20080113928 - Modified cea/b7 vector: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of... Agent: Patrick J. Halloran, Ph.d., J.d

20080113935 - Use of lipid conjugates in the treatment of diseases or disorders of the eye: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid... Agent: Pearl Cohen Zedek Latzer, LLP

20080113937 - Agent for preventing and ameliorating obesity: The present invention relates to raw materials for foods, pharmaceuticals, and the like, wherein the raw materials can be effective in preventing and ameliorating various lifestyle-related diseases such as obesity and hyperlipidemia, safe, applicable in wide areas, and less deteriorative to texture; and the present invention also relates to a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080113942 - Phosphorylcholine group-containing compound and method for producing same: e

20080113943 - Therapeutic beta-lactams:

20080113944 - Novel indole derivatives: 5-vinyl-indole derivatives are chemical uncouplers useful e.g. for the treatment of obesity.... Agent: Novo Nordisk, Inc. Patent Department

20080113900 - Pharmaceutical compositions and therapeutic applications for the use of a synthetic vitamin b12 derivative, glutathionylcobalamin: Therapeutic applications, such as prevention, treatment and supplementation, for the use of novel and other thiolatocobalamins to protect human cells against the effects of oxidative stress. In particular, this invention relates to the use of a novel synthetic thiolatocobalamin, glutathionylcobalamin to protect animal cells against oxidative stress damage. This invention... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20080113901 - Use of an agent that restores tissue perfusion and oxygenation: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080113903 - Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.... Agent: Emch, Schaffer, Schaub & Porcello Co

20080113916 - Povidone-containing carriers for polypeptide growth factors: A liquid carrier medium is provided which is suitable for solubilizing growth factors, such as mixtures of bone morphogenetic proteins, that are found to induce an angiogenic response in ischemic tissues. The liquid medium comprises an aqueous solution of polyvinyl pyrrolidone.... Agent: Williams, Morgan & Amerson

20080113915 - Sapap3 knockout mouse and clinical modeling associated with the sapap3 gene: Provided is a transgenic knockout mouse whose genome includes a disruption in its endogenous SAPAP3 gene, wherein the disruption results in the mouse exhibiting increased levels of anxiety as compared to a wild type mouse. Also provided are cells derived from the disclosed transgenic knockout mouse. Also provided are methods... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080113927 - Indolopyrrolocarbazole derivatives and anti-tumor agent: o

20080113930 - Compositions and methods for inhibiting expression of the pcsk9 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Fish & Richardson Pc

20080113931 - Rnai modulation of aha and therapeutic uses thereof: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Fish & Richardson Pc

20080113934 - Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders: A method of treatment of the human or non-human animal body for treating fibrin-dependent microcirculation disorders is disclosed, for example, microcirculation disorders caused by metabolic diseases, inflammatory reactions or autoimmune diseases; peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation comprising administering to a human or non-human animal... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080113936 - Process for the preparation of adsorbates of valsartan and/or its solvates or hydrates: The present invention relates to a process for the preparation of adsorbates of valsartan and/or its solvates or hydrates wherein one starts with a solution of valsartan or of one of its pharmaceutically acceptable salts and/or their solvates or hydrates in at least one organic solvent where the total water... Agent: J.c. Patents Suite 250

20080113938 - Accelerator for mineral absorption and use thereof: The present invention has an object to provide an accelerator for mineral absorption and a composition containing the accelerator. The object is solved by providing an accelerator for mineral absorption comprising cyclic tetrasaccharide and/or saccharide derivatives thereof and a composition containing the accelerator.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080113939 - Geranyl compounds: e

20080113940 - Insecticidal compositions:

20080113941 - Podophyllotoxin derivatives: 4-O esters of podophyllotoxin and 4′-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4′-demethylepipodophyllotoxin. The compounds are useful for treating cancer.... Agent: Foley & Lardner LLP

20080113945 - Compositions and methods for inhibiting cytochrome p450: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect... Agent: Proskauer Rose LLP

20080113946 - N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof: wherein Ar, A, Q and R1-R6 are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080113948 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.... Agent: Frommer Lawrence & Haug

20080113947 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of rosacea: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.... Agent: Frommer Lawrence & Haug

20080113950 - Drugs for chronic pains: Nitro-oxyderivative compounds or salts thereof having the following general formula (I): A-(B)b0-(C)o0-N02 wherein: c0 is an integer and is 0 or 1, b0 is an integer and is 0 or 1, A=R-TI-, wherein R is the radical of an analgesic drug for the chronic pain, in particular for the neuropathic... Agent: Arent Fox LLP

20080113951 - Treatment of inflammatory, cancer, and thrombosis disorders: A pharmaceutical composition and a method of treating inflammation in a mammal. The method administers the therapeutic composition to the mammal. The therapeutic composition includes: a standard therapeutic dose of a COX2 inhibitor consisting of celecoxib or rofecoxib; and low dose aspirin in an amount of 70-85 mg.... Agent: Schmeiser, Olsen & Watts

20080113949 - Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention: This invention relates to a method of preventing stroke or reducing the risk of stroke in a patient in need thereof, especially in a patient at risk for a stroke or a secondary stroke, using dipyridamole in combination with acetylsalicylic acid (ASA) and an angiotensin II antagonist, corresponding pharmaceutical compositions,... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080113952 - Combination therapy for treating heart disease: A combination therapy and co-therapy method for administering therapeutic doses of an aldosterone antagonist agent and a metolazone-related compound to a subject in need of treatment for hypertension, congestive heart failure, and chronic kidney disease are provided. A pharmaceutical composition comprising these therapeutic agents is also provided.... Agent: Casimir Jones, S.c.

20080113953 - Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability: Methods of improving the bioavailability of ethinyl estradiol by orally administering to a patient a solid dosage form containing ethinyl estradiol or prodrug thereof where that dosage form releases at least some of the ethinyl estradiol or prodrug thereof in the oral cavity for absorption through the oral mucosa to... Agent: Fitzpatrick Cella Harper & Scinto

20080113954 - Supramolecular metallic complexes exhibiting both dna binding and photocleavage: Supramolecular complexes that target and cleave DNA are provided. The supramolecular complexes include at least one metal-to-ligand charge transfer (MLCT) light absorbing unit, at least one Pt based DNA binding unit, and at least one bridging unit that serves to connect the components. The Pt-based DNA binding unit binds the... Agent: Whitham, Curtis & Christofferson & Cook, P.c.

20080113955 - Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin: Methods of treating infant hyperbilirubinemia using stannsoporfin are disclosed. The methods of the invention permit treatment of various patient populations at lower doses of stannsoporfin than previously believed effective, providing advantages in therapeutic administration.... Agent: Morrison & Foerster LLP

20080113956 - Substituted porphyrins: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such... Agent: Sheridan Ross Pc

20080113958 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien, Ph.d. Miller, Canfield, Paddock And Stone, P.L.C

20080113957 - Preparation and use of compounds as protease inhibitors: e

20080113959 - {beta}-lactamyl vasopression v1a antagonists and methods of use: Novel 2-(azetidin-2-on-1-yl) alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl) alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.... Agent: Barnes & Thornburg LLP

20080113960 - Combinations comprising a low molecular weight thrombin inhibitor and a prodrug of a low molecular weight thrombin inhibitor: According to the invention there is provided a kit of parts comprising: (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and (b) a pharmaceutical formulation including a prodrug of a low... Agent: Nixon & Vanderhye, Pc

20080113961 - Heterocyclic compound: A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof. The compound has a general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080113962 - Condensed tricyclic benzimidazoles for the treatment of gastrointestinal disorders: c

20080113963 - Cyclic benzimidazoles: The invention is directed to processes for preparing cyclic benzimidazoles, which compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.... Agent: Nath & Associates Pllc

20080113964 - 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3h)-one derivatives and their use as progesterone receptor modulators: e

20080113965 - Skeletal muscle protecting agent: The present invention provides a novel drug which is useful as a skeletal muscle protecting agent comprising a compound having inhibitory activity against squalene synthase or a salt thereof, or a prodrug thereof.... Agent: Edwards Angell Palmer & Dodge LLP

20080113966 - Cgrp receptor antagonists: Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster... Agent: Merck And Co., Inc

20080113967 - Enzyme modulators and treatments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or... Agent: Hovey Williams LLP

20080113968 - Substituted piperazines and diazepanes: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor... Agent: Novo Nordisk, Inc. Patent Department

20080113969 - Combination therapy for the treatment of pain: The present invention provides synergistic combinations for the treatment of conditions associated with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain associated with migraine. In particular, the present invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with... Agent: Christopher A. Klein King Pharmaceuticals, Inc.

20080113970 - Transnasal anticonvulsive pharmaceutical composition: The anticonvulsive pharmaceutical composition for transmucosal delivery of diazepam according to the present invention includes a minimized content of water and ethanol, a fatty acid ester as a main ingredient and no use of a polar solvent, e.g. glycol, and, exhibits improved diazepam solubility and transmucosal permeability due to using... Agent: Gibbons P.c.

20080113972 - 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors: The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders... Agent: Bayer Health Care Llc

20080113971 - Pyrazole compounds as protein kinase inhibitors: Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of making such compounds are described, as well as a method of using them for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, where the... Agent: Pfizer Inc

20080113973 - Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxygenase-2: The invention is directed to methods and compositions that can be used in the treatment of inflammation, pain and cardiovascular disorders. Methods and compositions are described involving the combination of a thromboxane A2 receptor antagonist and an inhibitor specific for cyclooxygenase-2.... Agent: Law Office Of Michael A. Sanzo, Llc

20080113974 - Heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them.: e

20080113976 - N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity:

20080113975 - Thiourea compounds:

20080113977 - Mixed lineage kinase modulators: The present invention provides a compound of the formula: (Formula I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering... Agent: Eli Lilly & Company

20080113978 - Imidazopyridazine compounds: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.... Agent: Eli Lilly & Company

20080113979 - Fungicidal mixtures of thiophene derivative: Disclosed are fungicidal mixtures, compositions and methods for controlling plant diseases relating to combinations comprising (a) N-[2-(1,3-dimethyl-butyl)-3-thienyl]-1-methyl-3-(tri-fluoromethyl)-1H-pyrazole-4 carboxamide (including all stereoisomers) or an agriculturally suitable salt thereof; and (b) at least one compound selected from the group consisting of compounds of Formula III or Formula IV which act at the... Agent: David E Heiser E I Dupont De Nemours And Company

20080113980 - Substituted-2-imidazoles: The invention relates also to processes for preparing such compounds, compositions comprising such a compound or a pharmaceutically-acceptable acid addition salt thereof, and a method of treating a disease or disorder in a patient comprising administering such a compound, or pharmaceutically-acceptable acid addition salt thereof, to a patient in need... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080113982 - Azacyclosteroid histamine-3 receptor ligands: Azacyclosteroid histamine-3 receptor ligands, pharmaceutical compositions comprising such compounds, and methods for using such compounds and compositions are described herein.... Agent: Paul D. Yasger Abbott Laboratories

20080113981 - Diaryl ether beta2 adrenergic receptor agonists: The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080113983 - Nicotinic acetylcholine receptor ligands: Acetylcholine receptor ligands of formula I wherein A, Ar1 and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080113984 - 3-aryl-6-aryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof: wherein Ar1, Ar2, and X are defined herein. The present invention relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080113985 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Inc.

20080113987 - Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient: A novel method for immunosuppressive in a mammal suffering from an immune disease, including administering to the mammal a therapeutically effective amount of a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof is... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080113986 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders than involve abnormal activation of the Abl, Bcr-abl, Bmx, c-RAF, CSK, Fes, FGFR3,... Agent: Genomics Institute Of The Novartis Research Foundation

20080113988 - Isoxazoline-indole derivatives with an improved antipsychotic and anxiolytic activity: The present invention relates to novel isoxazoline-indole derivatives according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, with a binding affinity towards dopamine receptors, in particular towards dopamine D2 and/or D3... Agent: Woodcock Washburn LLP

20080113989 - Novel substituted amides, their preparation and use: e

20080113990 - Biphenyl derivatives as modulators of voltage gated ion channels: Biphenyl derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Inc.

20080113991 - Pyridopyrazines and the use thereof as kinase inhibitors: The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general Formula I, their preparation and use as medicaments, in particular for the treatment of malignant and other disorders based on pathological cell proliferations.... Agent: Goodwin Procter L.l.p Attn: Patent Administrator

20080113993 - Barbituric acid analogs as therapeutic agents: This invention pertains to active barbituric acid analogs which inhibit HIF-1 activity (e.g., the interaction between HIF-1$g(a) and p300) and thereby inhibit angiogenesis, tumorigenesis, and proliferative conditions, such as cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080113992 - Dihydropteridione intermediate compounds: i

20080113994 - Annelated quinoline derivatives as pesticide:

20080113995 - Substituted homopiperidine, piperidine or pyrrolidine derivatives: A novel class of substituted homopiperidine, piperidine and pyrrolidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor antagonistic activity and are thus useful in the treatment of... Agent: Novo Nordisk, Inc. Patent Department

20080113996 - Medicaments: Methods of prevention or treatment of renal diseases or conditions associated with abnormal ion flux, in particular autosomal dominant polycystic kidney disease, with a modulator of human peroxisome proliferator activated receptor gamma.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080113997 - Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor: t

20080113998 - 1-phenyl-3-piperazine-pyrazoles and pesticidal compositions of matter thereof: The invention relates to 5-diazacycloalkylpyrazole derivatives of the formula (I) or salts thereof a process for their preparation, to compositions thereof and to their use for the control of pests, including arthropods and helminths.... Agent: Frommer Lawrence & Haug

20080113999 - Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states: e

20080114000 - Suppressor of excess accumulation of intracellular sodium ions: A medicament for suppressing intracellular excess accumulation of sodium ions and a medicament for therapeutic and/or preventive treatment of cardiac disorders resulting from cardiosurgery operations which comprises an aminobenzenesulfonic acid derivative represented by the following general formula (I) or a salt thereof, or a hydrate thereof or a solvate thereof... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080114001 - Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity: The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, especially for the curative and/or prophylactic treatment of leukemia, myelodysplastic syndromes or pulmonary hypertension, and to a method of... Agent: Novartis Corporate Intellectual Property

20080114003 - Pyrimidinylisoxazole derivatives: e

20080114004 - Hydrazone derivatives as kinase inhibitors:

20080114002 - Substituted acids for the treatment of respiratory diseases: The invention relates to substituted acids of formula (I), where T, W, X, Y, Z, R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.... Agent: Fish & Richardson P.c.

20080114005 - Fibrate compounds having ppar agonist activity: There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from —CH2—, —O—, —NH—, and —S—; Y is chosen from —O—, —NH—, and —S—; Z, which... Agent: Dr. Reddy's Laboratories, Inc.

20080114006 - Kinase inhibitors useful for the treatment of proliferative diseases: The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase... Agent: Hovey Williams LLP

20080114007 - 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase: e

20080114008 - Quinazoline derivatives as antiviral agents: Compounds of formula (I) are found to be active in inhibiting replication of flaviviridac Formula (I) wherein: X represents a direct bond or a moiety -L-NR—, wherein R is hydrogen or C1-C4 alkyl, and L represents a C1-C4alkylene, C6-C10 aryl or 5- to 10-membered heteroaryl moiety; either R1 and R2,... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080114009 - Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer: (−)-5-(3-Chlorophenyl)-α-(4-chlorophenyl)-α-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer... Agent: Philip S. Johnson Johnson & Johnson

20080114010 - Novel substituted imidazole compounds: Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080114011 - Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080114014 - New uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium: A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates... Agent: Brown & Michaels, Pc 400 M & T Bank Building

20080114013 - Spiroindolinone derivatives: m

20080114012 - Tricyclic compound and use thereof:

20080114015 - Nf-kb inhibitors and uses thereof: A diastereomers of imidazolines as 4-position acids are described. The imidazoline diastereomers potentiate the activity of antitumor drugs and are potent inhibitors of the transcription factor NF-κB.... Agent: Ian C. Mcleod Mcleod & Moyne, P.c.

20080114016 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise fused pyrazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by ad-ministering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20080114017 - Novel indolopyridines, benzofuranopyridines and benzothienopyridines: e

20080114018 - Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands: A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile,... Agent: Foley And Lardner LLP Suite 500

20080114020 - Difluoro-substituted imidazopyridines: c

20080114019 - Hydroxylamine substituted imidazoquinolines: Imidazoquinoline compounds with an oxime substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.c.

20080114021 - Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent: The invention relates to the areas of therapeutics, pharmaceuticals, drug discovery, and immunotherapy. More specifically, the present invention relates to methods of stimulating the immune system through the administration of flavone acetic acid [FAA] analogues, and in particular, the flavone acetic acid analogue, 5,6-dimethylxanthenone-4-acetic acid (DMXAA) so as to comprise... Agent: Edell Shapiro & Finnan , Llc

20080114023 - Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20080114022 - Pyrrolopyridine derivatives and their use as crth2 antagonists: e

20080114024 - 1,6 naphthyridines useful as inhibitors of syk kinase:

20080114025 - Cardiovascular compositions and methods using combinations of anti-platelet agents: A method and composition for inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The composition preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents. Specific preferred embodiments of the solution of the present invention for... Agent: Omeros Medical Systems, Inc.

20080114026 - N,n'-diphenylurea derivatives which are suitable as kinase inhibitors: Compounds of the formula (I), in which R1a—R1c, R2a, R2b, R3 and R5 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Baker & Daniels LLP

20080114027 - Method for treating delirium: Methods for treating delirium, including postoperative delirium, sepsis-associated delirium, and drug or alcohol withdrawal-associated delirium with ibudilast are disclosed. Treatment may further comprise administration of one or more other agents, such as analgesics, anti-inflammatory and central nervous system (CNS)-partitioning phosphodiesterase inhibitors, antidepressants, neuroleptics, benzodiazepines, and procholinergic agents.... Agent: Robins & Pasternak LLP

20080114028 - Process for preparing polymorphic forms of solifenacin succinate: Polymorphic forms of solifenacin have been prepared and characterized. These polymorphic forms are particularly useful in pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20080114029 - Polymorphs of solifenacin intermediate: Polymorphic forms of 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline have been prepared and characterized. These polymorphic forms are particularly useful for preparing solifenacin salts.... Agent: Kenyon & Kenyon LLP

20080114030 - Diarymethyl and related compounds: wherein R1, R2, R3, R4, R5, R6, R7, Ar1, Ar2, E, a, b, c and z are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore,... Agent: Theravance, Inc.

20080114032 - Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor: The present invention relates to the use of 1-ar(alk)ylimidazolin-2-ones which contain a disubstituted amine radical in the 4-position for the treatment or prevention of central nervous system disorders including depression, anxiety, movement disorders, and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated to other mental disorders.... Agent: Fulbright & Jaworski, LLP

20080114031 - Monosaccharide derivatives: The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis,... Agent: Jayadeep R. Deshmukh, Esq. Ranbaxy Inc.

20080114033 - Pyridinone compounds: e

20080114034 - 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists: Compounds of the formula (1): in which A, R1, R2 and R3 are as defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.... Agent: Millen, White, Zelano & Branigan, P.c.

20080114035 - Novel intermediate compounds useful in the preparation of oxazoles and pharmaceutical actives for the regulation of lipid and glucose metabolism: wherein the R1-R7 groups or substituents are defined herein. The present invention also comprises improved methods in the preparation of oxazoles in which the compounds of Formula III are intermediates and which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080114036 - Novel compounds, their preparations and use: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of... Agent: Novo Nordisk, Inc. Patent Department

20080114037 - Histone deacetylase inhibitors: v

20080114038 - Drugs derived from diclofenac containing no-donor heterocycles, composition and method of inflammation treatment: The present invention refers to drugs resulting from the pharmaceutical substance diclofenac, relative to the formula. The invention further refers to a pharmaceutical composition, which involves the said drugs and a pharmaceutically adequate vehicle. It is also described a method for the treatment of inflammation through the administration of the... Agent: Merek, Blackmon & Voorhees, Llc

20080114039 - Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with... Agent: Jones Day

20080114040 - Epothilone derivatives: Epothilone derivatives of Formula (I) and their use as a pharmaceutical.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080114041 - Benzothiazolesulfonamides: o

20080114042 - Compound:

20080114043 - Medicinal composition for inhalation: A medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist topically exhibits a prolonged bronchodilating and antiinflammatory effects. Namely, the medicinal composition for inhalation containing a continuous-release type prodrug of an EP2 agonist is useful as a safe preventive and/or a remedy for respiratory diseases (for... Agent: Sughrue-265550

20080114044 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.... Agent: Genomics Institute Of The Novartis Research Foundation

20080114045 - Process for the production of candesartan: The present invention relates to novel processes for the preparation of candesartan or of a protected form of candesartan, of a candesartan salt or of a candesartan ester; compounds which can be used in processes according to the invention, processes for their preparation, their use in processes according to the... Agent: Hedman & Costigan P.c.

20080114046 - Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors: The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080114047 - Cationic substituted benzofurans as antimicrobial agents: A method of treating a Mycobacterium tuberculosis infection in a subject in need thereof by administering to the subject an effective amount of a cationic substituted benzofuran compound. Methods of treating microbial infections, including infections from protozoan pathogens, such as Leishmania donovani, Trypanosoma brucei rhodesiense, a Trypanosoma cruzi, and Plasmodium... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080114048 - Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.... Agent: Philip S. Johnson Johnson & Johnson

20080114049 - Chemical compounds: The present invention relates to (1S,6R)-6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane, pharmaceutically acceptable salts, prodrugs or solvates thereof; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080114050 - Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof: Pyrrole-oxindole derivatives useful as progesterone receptor antagonists, and methods for preparing the same, are provided. Pharmaceutical compositions containing these derivatives are described, as is the use thereof in contraception and hormone-related conditions.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080114051 - Pyrrolidine derivatives as prostaglandin modulators: Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080114052 - Cyclic derivatives as modulators of chemokine receptor activity: b

20080114053 - Method for producing fluorinated proline derivative: (In the formula, R1 and R2 are defined as in the general formula (1)) is reacted with a fluorination agent to obtain a reaction product containing the compound represented by the general formula (2) and a by-products; and bringing chlorine, bromine, iodine, hypochlorous acid, hypochlorite, hypobromous acid, hypobromite or N-halogenosuccinimide... Agent: Buchanan, Ingersoll & Rooney Pc

20080114054 - Compositions and methods for reducing antimicrobial resistance of microbes: The instant methods and compositions represent an improvement in reducing antimicrobial resistance of microbes and enhancing antimicrobial activity of drugs. A composition comprising of polyphenols, an ascorbic compound, L-lysine, L-proline, and L-arginine have been found to reduce the antimicrobial resistance of microbe. As such, methods of treating infection, and methods... Agent: Inhouse Co.

20080114055 - Thioxanthone compounds to reverse weight loss: One embodiment of the invention uses thioxanthone compounds containing a choline or choline analogue moiety, such as CCcompound1 or [3-(3,4-Dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethyl-ammonium chloride, to reduce or reverse body weight loss in various mouse models of human tumors. Another embodiment of the invention discloses a method for reducing or reversing cachexia or disease-induced... Agent: Faegre & Benson LLP Patent Docketing

20080114056 - Chromone derivatives useful as vanilloid antagonists: e

20080114057 - Compositions and methods for the treatment of inflammatory conditions of the mucosae, skin and the eye: The present invention relates to compositions comprising a proanthocyanidin, as well as methods for using such compositions in the treatment of an inflammatory condition of the skin including, but not limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitis, psoriasis, xerosis and atopia, as well as treatment of an... Agent: Marshall, Gerstein & Borun LLP

20080114058 - Use of lignan compounds for treating or preventing inflammatory disease: The present invention relates to the use of lignan compounds for treating or preventing an inflammatory disease. More particularly, it relates to a pharmaceutical composition for the treatment or prevention of an inflammatory disease, comprising a lignan compound represented by Formula I, as well as a treating method and the... Agent: Jhk Law

20080114059 - Novel compounds for treatment of cardiac arrhythmia and methods of use: The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080114060 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isoomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.... Agent: Frommer Lawrence & Haug

20080114061 - Diphenylethylene compounds and uses thereof: The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing... Agent: Jones Day

20080114062 - Modulator: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR1 or NR1R2 wherein each of R1 and R2 is independently H, or a hydrocarbyl group; X is an alkylene, alkenylene, or alkynylene group, each of which may be optionally substituted... Agent: Nixon & Vanderhye, Pc

20080114063 - Use of 2,5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases: The present invention relates to the use of a compound of Formula (I′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's... Agent: Frommer Lawrence & Haug

20080114064 - Tri(hydroxymethyl)methylamine salt or an ethanol amine salt of (2s)-2-ethoxy-3-(4-phenyl) propanoic acid: The invention relates to a compound selected from one or more of the following: a tris (hydroxymethyl) methylamine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl (2-phenylethyl) amino]-2-oxoethoxy}phenyl) propanoic acid; an ethanol amine salt of (2S)-2-ethoxy-3-(4-{2-[hexyl (2-phenylethyl) amino]-2-oxoethoxy}phenyl) propanoic acid; or a pharmaeutical composition comprising the compound.... Agent: Pepper Hamilton LLP

20080114065 - Methods for the treatment of hiv-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology: Methods for treating or preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation are disclosed. The compositions contain a conjugated fatty acid, a thiol-containing compound and a bioavailable form of trivalent chromium.... Agent: Dr. John G. Babish Bionexus

20080114066 - Synergistic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function: The present invention provides compositions and methods for increasing the absorption of dietary carotenoids in humans. The methods and compositions of the invention can used to increase the concentration of retinal lutein and zeaxanthin, thereby preventing the onset and/or slowing the progression of macular degeneration. Pharmaceutical compositions comprising a therapeutically... Agent: Nutter Mcclennen & Fish LLP

20080114067 - Composition for recovery from or prevention of central nervous system fatigue: A composition for recovery from or prevention of central nervous system fatigue (brain fatigue), comprising as active ingredients at least any amino acid selected from the group consisting of tyrosine, methionine, phenylalanine and glutamine, especially methionine and phenylalanine together with a branched chain amino acid of L-valine, L-leucine or L-isoleucine.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080114068 - Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors: c

20080114069 - Methods of inducing terminal differentiation: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high.... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20080114070 - Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis: Methods and compositions for restoring sensitivity to the antitumorigenic effects of antiestrogen therapy and/or cytotoxic therapy and inducing cell apoptosis are provided. Contacting tumor cells to GP88 antagonists (e.g., anti-GP88 antibodies, anti-GP88 antisense nucleic acids, GP88 siRNA, and small molecules) induces apoptosis and restores sensitivity to the antitumorigenic effects of... Agent: Dickstein Shapiro LLP

20080114071 - Processes for preparing sertraline: Provided are processes for the preparation of sertraline and sertraline hydrochloride.... Agent: Kenyon & Kenyon LLP

20080114072 - N1,n4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and methods thereof: N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as MDL 72,527 and N,N′-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any... Agent: Quarles & Brady LLP

20080114073 - 2,4,6,-trisubstituted phenols having anesthetic properties: Trisubstituted phenol compounds and methods of using the compounds, e.g., for anesthetizing a subject, are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20080114074 - Anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation: An anti-atherosclerosis composition comprising a LDL-oxidation inhibiting effective amount of phytoene, phytofluene or mixtures thereof and a method for inhibiting the progression of atherosclerosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080114075 - Use of 2,5-dihydroxybenzene derivatives for treating dermatitis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.... Agent: Frommer Lawrence & Haug

20080114076 - Punctal plug comprising a water-insoluble polymeric matrix: Disclosed is a pharmaceutical composition comprising a water insoluble polymer matrix that comprises a bioerodable polyester polymer or a fatty acid based polyester polymer, or a mixture of both polymers, wherein the polymer matrix has a melting point of less than 60° C., and wherein the composition is liquid or... Agent: Alcon

20080114077 - Symmetrically branched polymer conjugates and microarray assays: Modified symmetrically branched polymers are combined with bioactive agents for a variety of purposes including drug delivery and conjugation to one member of a binding pair for use in an assay.... Agent: Bell, Boyd, & Lloyd LLP

20080114078 - Rgd-enriched gelatine-like proteins with enhanced cell binding: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Roger Pitt Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080114079 - Trpm2-specfic inhibitors: The present invention relates to methods and compositions for modulating ADPR-mediated migratory activity of cells through regulation of the TRPM2 cation channel. Such methods and compositions may be used for the treatment of disorders including, but not limited to, inflammation, ischemia, atherosclerosis, asthma, autoimmune disease, diabetes, arthritis, allergies, and transplant... Agent: Kenyon & Kenyon LLP

20080114080 - Compositions and methods for the treatment of cystic fibrosis and other pulmonary disorders: A screening assay to identify agents which act synergistically to compensate for defective chloride ion transport in cells harboring a mutation in the CFTR in provided.... Agent: Dann, Dorfman, Herrell & Skillman

20080114081 - Methods for diagnosis and treatment of ph domain signal transduction disorders: Methods for treatment, diagnosis, and screening are provided for diseases or conditions characterized by an abnormality in a signal transduction disorder. The signal transduction pathway involves an interaction between a PH domain and a PH domain binding partner.... Agent: Foley And Lardner LLP Suite 500

20080108549 - Actin proteins as biomarkers for indication and targeting of resistance and sensitivity to an abl kinase inhibitor in patients with chronic myelogenous leukemia: The invention relates to 5 identified protein biomarkers, gamma- and beta-Actin proteins, for screening, diagnosis, drug targeting, and drug design for resistance of cancer to an Ab1 kinase inhibitor. The method is based on the use of two-dimensional (2D) gel electrophoresis to separate the complex mixture of proteins found in... Agent: Power3 Medical Products, Inc.

20080108548 - Food composition for rapidly attenuating inflammatory responses: The invention pertains to the use of a lipid fraction and/or a protein fraction for the manufacture of a composition for causing an immediate attenuation of the inflammatory response. The lipid and/or protein stimulate the parasympathetic nervous system centrally or peripherically via the gastrointestinal tract leading to rapid attenuation of... Agent: Foley And Lardner LLP Suite 500

20080108550 - Hdl for the treatment of stroke and other ischemic conditions: The present invention relates to a method for the prophylaxis and/or treatment of stroke and other ischemic injury, wherein HDL is administered to a subject in need thereof, particularly by intravenous infusion.... Agent: Foley And Lardner LLP Suite 500

20080108545 - Peptide nucleic acid conjugates and uses thereof: The invention provides a triphenylphosphonium peptide nucleic acid conjugate. The conjugate comprises a peptide nucleic acid linked via a disulfide bond, to a triphenylphosphonium group. Conjugates of the invention can be used to deliver PNA oligomers across the plasma membrane into cells.... Agent: Jacobson Holman Pllc

20080108547 - Protease inhibitor: The present disclosure provides isolated nucleic acids and their resulting polypeptides from Saccharophagus degradans strain 2-40, which may be utilized as protease inhibitors.... Agent: Carter Deluca Farrell & Schmidt

20080108557 - Modified proteins: A method of conjugating peptides and proteins by means of glycosyltransferase is provided.... Agent: Novo Nordisk, Inc. Patent Department

20080108561 - Dna sequence, and recombinant preparation of group 4 major allergens from cereals: The invention relates to the preparation of DNA sequences of group 4 major allergens from cereals. The invention also includes fragments, novel combinations of partial sequences and point mutations with hypoallergenic effects. The recombinant DNA molecules and the derived polypeptides, fragments, novel combinations of partial sequences and variants can be... Agent: Millen, White, Zelano & Branigan, P.c.

20080108565 - Hepatocyte growth factor (hgf) binding proteins: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain... Agent: Goodwin Procter LLP

20080108560 - Heterologous g-csf fusion proteins: The present invention encompasses heterologous fusion 5 proteins comprising a hyperglycsoylated G-CSF analog fused to proteins such as albumin and the Fc portion of animmunoglobulin which act to extend the in vivo half-life of the protein compared to native G-CSF. These fusion proteins are particularly suited for the treatment of... Agent: Eli Lilly & Company

20080108567 - Leptin-related peptides: The present invention relates to methods and compositions containing novel leptin peptides, preferably for the modulation of body mass (i.e., weight), more specifically for novel diagnostic and therapeutic applications in homeostasis of body weight and adipose tissue mass.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c.

20080108564 - Novel peptides that bind to the erythropoietin receptor: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also... Agent: Darby & Darby P.c.

20080108563 - Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same: The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies... Agent: Heller Ehrman LLP

20080108562 - Treatment of bone metastases by means of pth receptor agonists: Symptoms associated with the growth of bone-metastasized cancer or bone-originated cancer, such as bone loss, bone fracturing, and pain, can be ameliorated by administering a effective amount of a PTH receptor agonist, which can be PTH, a PTH fragment, or an analog thereof or parathyroid hormone-related protein, a fragment or... Agent: Foley And Lardner LLP Suite 500

20080108573 - Compositions and methods for treatment of cardiovascular disease: The present invention is concerned with composition and methods for treatment of certain cardiovascular conditions. In particular it is concerned with prophylactic or therapeutic treatment of myocardial fibrosis or associated conditions by administering compositions comprising vasoactive intestinal peptide (VIP) and/or active fragments) thereof.... Agent: Goodwin Procter LLP Patent Administrator

20080108578 - Method for producing carbohydrate partial esters: A process for the production of carbohydrate partial esters by transesterification of glycoses with fatty acid esters in the presence of emulsifiers and a catalyst mixture, to produce products with utility in the production of foods, cosmetic preparations, and in superabsorbancy applications.... Agent: Cognis Corporation Patent Department

20080108581 - Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs: The invention relate to the use of a compound of formula A-B—C Wherein A is a DNA sequence-specific ligand capable of simultaneously and specifically recognizing a sequence common to genes of pathological interest; B is a linker arm, said linker arm being bound to the 3′ end of A; C... Agent: Nixon & Vanderhye, Pc

20080108582 - Methods and compositions for combinatorial approaches to cancer gene therapy: The present invention provides a nucleic acid comprising a) a nucleotide sequence encoding one or more pro-apoptotic proteins, and b) a nucleotide sequence encoding one or more tumor-specific and/or tissue-specific promoters. Also provided is a method of treating cancer, comprising administering the compositions of this invention to a subject.... Agent: Myers Bigel Sibley & Sajovec

20080108552 - Hyd1 peptides as anti-cancer agents: The present invention concerns fragments and variants of the HYD1 peptide; polynucleotides encoding the peptides; host cells genetically modified with the polynucleotides; vectors comprising the polynucleotides; compositions containing these peptides, polynucleotides, vectors, or host cells; and methods of using the peptides, polynucleotides, vectors, and host cells as inhibitors of aberrant... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080108546 - Novel human card-only protein that inhibits pro-il-1 beta maturation: The present invention relates to a novel member of the card protein family. More specifically, it relates to a novel human card-only protein. The invention relates further to the use of this protein to inhibit pro-interleukin-1β maturation, preferably without inducing NF-κB activity or apoptosis.... Agent: Trask Britt

20080108553 - Rationally designed media for cell culture: This invention relates to methods for rationally designing cell culture media for use in cell cultures, e.g., cell cultures employed in polypeptide production; cell culture media designed with the disclosed methods; methods of producing a polypeptide of interest, e.g., an antibody, using such media; polypeptides produced using the methods and... Agent: Fitzpatrick Cella (wyeth)

20080108551 - Treatment of wounds: The invention generally provides compositions and methods that promote wound healing. Such compositions comprise isolated L. sericata polypeptides having serine protease activity. Desirably, the serine protease degrades fibronectin. The invention further provides biologically active fragments of fibronectin that promote wound healing that are the degradation products of incubation with ES.... Agent: Edwards Angell Palmer & Dodge LLP

20080108554 - Method and apparatus for producing dry particles: Method and apparatus for producing dry particles. Two liquid components are combined in a static mixer, atomized into droplets, and the droplets dried to form dry particles. Use of the static mixer enables incompatible liquid components to be rapidly and homogeneously combined. The present invention optimizes process conditions for increasing... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080108556 - Anti-angiogenic methods and compositions: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.... Agent: Robins & Pasternak

20080108555 - Method and apparatus for preparing an acellular red blood cell substitute: A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080108558 - Cross-linked glycopeptide-cephalosporin antibiotics: This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080108559 - Compositions and methods for treating diseases through inhibition of dna methylation and histone deacetylase: Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer and hematological disorders by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of... Agent: Wilson Sonsini Goodrich & Rosati

20080108566 - Analogues of glp-1: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.... Agent: Biomeasure Incorporated

20080108569 - Compositions and methods for treating diseases associated with phlpp: The present invention relates generally to PHLPP, a novel phosphatase that inactivates Akt (protein kinase B) by directly dephosphorylating the hydrophobic domain of the C-terminus. More specifically, the invention relates to PHLPP polynucleotides and the polypeptides encoded by these polynucleotides and the use of these polynucleotides and polypeptides in the... Agent: Biotactica, Llc

20080108568 - Compounds for improving learning and memory: e

20080108572 - Methods and compositions for control of fetal growth via modulation of relaxin: The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to... Agent: Robins & Pasternak

20080108570 - Pharmaceutical compositions containing botulinum toxin: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000... Agent: Allergan, Inc.

20080108571 - Unitary combinations of fsh and hcg: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the... Agent: Foley And Lardner LLP Suite 500

20080108574 - Melanocortin receptor mediated modulation of neurogenesis: The present disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a melanocortin receptor (MCR) modulating agent, optionally in combination with one or more other neurogenic agents,... Agent: Townsend And Townsend And Crew, LLP

20080108575 - Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications: Preparation of AT1 receptors antagonists formulations using the cyclodextrins, their derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular disease and their complications. Until now, no applications using the AT11 receptor antagonists and cyclodextrins or derivatives and/or biodegradable polymers for the treatment of arterial hypertension, other cardiovascular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080108576 - Novel cytostatic conjugates with integrin ligands: The present invention relates to cytostatics which have a tumour-specific action as a result of linkage to αvβ3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumour tissue. The preferred linking units provide sufficient stability... Agent: Bayer Health Care Llc

20080108577 - Tissue adhering compositions: A method mixes a first component, a second component, and a buffer material. The first component includes an electrophilic polymer material comprising poly(ethylene glycol) having a functionality of at least three. The second component includes a nucleophilic material comprising a natural or synthetic protein at a concentration of about 25%... Agent: Daniel D. Ryan Ryan Kromholz & Manion, S.c.

20080108579 - Enhanced ocular neuroprotection and neurostimulation: An ocular method comprising non-systemic localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neurostimulatory and/or neuroprotective macrolide or other agent for a duration sufficient to enhance viability, confer protection, reduce degeneration of retinal neural cells. The method is used in a patent having... Agent: Thompson Hine L.l.p. Intellectual Property Group

20080108580 - Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof:

20080108584 - Compositions and methods for inhibiting expression of ikk-b gene: The invention relates to a doable-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the... Agent: Fish & Richardson Pc

20080108585 - Dna vaccination for treatment of autoimmune disease: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive... Agent: Townsend And Townsend And Crew, LLP

20080108583 - Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes: The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method... Agent: Cooper & Dunham, LLP

20080108586 - Combination therapy for human immunodeficiency virus infection: The present invention is directed to combination therapies for treatment of Human Immunodeficiency Virus (HIV) infection comprising administration of a CCR5 antagonist in combination with other therapeutic agents.... Agent: Fish & Richardson Pc

20080108587 - Cartilage regeneration promoting agent: An object of the present invention is to provide an excellent cartilage regeneration-promoting agent that can promote regeneration of cartilage efficiently and is highly safe, and a medicine and a food that utilizes the cartilage regeneration-promoting agent. Thus, the present invention relates to a cartilage regeneration-promoting agent that includes at... Agent: Arthur G. Schaier Carmody & Torrance LLP

20080108588 - Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate): The invention relates to compositions and methods for use in treating skeletal system disorders in a vertebrate at risk for bone loss, and in treating conditions that are characterized by the need for bone growth, in treating fractures, and in treating cartilage disorders. More specifically, the invention concerns the use... Agent: Morrison & Foerster LLP

20080108589 - Method of treatment with coadministration of aspirin and prasugrel: A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080108590 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Synnestvedt & Lechner, LLP

20080108591 - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses: p

20080108592 - New method: The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer.... Agent: Fish & Richardson P.c.

20080108593 - Allergen decomposer and antiallergenic feathers: e

20080108595 - Inhibitors of cathepsin s: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively... Agent: Genomics Institute Of The Novartis Research Foundation

20080108594 - Antithrombotic ethers: This application relates to a compound of formula I (or a pro-drug thereof or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and... Agent: Eli Lilly & Company

20080108596 - Combination of quetiapine and zolmitriptan: The present invention relates to a combination comprising quetiapine or a pharmaceutically acceptable salt thereof and zolmitriptan or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, processes for its preparation, the use thereof in the manufacture of a medicament and a method of treatment of disease and more particularly to a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080108597 - New use of quetiapine: The present invention relates to methods of treating Attention Deficit Hyperactivity Disorder, Conduct Disorder and related conditions and disorders.... Agent: Pepper Hamilton LLP

20080108598 - Pharmaceutical use of substituted amides: The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture... Agent: Novo Nordisk, Inc. Patent Department

20080108599 - Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders: e

20080108600 - Polycyclic pyridines as potassium ion channel modulators: The present invention provides a genus of polycyclic pyridines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods.... Agent: Townsend And Townsend And Crew, LLP

20080108601 - Sulfonyl-derivatives as novel inhibitors or histone deacetylase: e

20080108602 - Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.... Agent: Fish & Richardson Pc

20080108605 - Anxiolytic agents with reduced sedative and ataxic effects: Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.... Agent: Wisys Technology Foundation, Inc. C/o Mirick, O'connell, Demallie & Lougee, LLP

20080108603 - Combination therapy for the treatment of pain: The present invention provides synergistic combinations for the treatment of conditions associated with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain associated with migraine. In particular, the present invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with... Agent: King Pharmaceuticals, Inc.

20080108604 - Novel lactam compound: The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080108606 - Conjugated psychotropic drugs and uses thereof: Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.... Agent: Martin D. Moynihan

20080108607 - Compositions for controlling plant pests: v

20080108608 - Pyrimidines with tie2 (tek) activity: The invention relates to a compound of the Formula (I). or salt thereof wherein R1, R2, R3, R4, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and... Agent: Astrazeneca R&d Boston

20080108609 - Benzoxazole carboxamides for treating cinv and ibs-d: e

20080108610 - Selected benzofuran derivatives: The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds, and especially their use as anti-infectives.... Agent: Dickstein Shapiro LLP

20080108613 - Pyrazolopyrimidine compounds as antitumor agents: The invention concerns compounds of the formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.... Agent: Morgan Lewis & Bockius LLP

20080108611 - Substituted thienopyrimidine kinase inhibitors: e

20080108612 - Use of purine derivatives as hsp90 protein inhibitors: This invention relates to methods of inhibiting the Hsp90 chaperone protein, and methods of treatment comprising administration of compounds of formula (IA) (IB) and (II)... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080108614 - Substituted 2-amino-quinazolin-4-cn compounds for use in the treatment of cns disorders, pain, stroke, addiction and epilepsy, their preparation and use as intermediates: The present invention relates to substituted quinazoline compounds, methods for their preparation, as well as their use as intermediates for the preparation of active biomolecules.... Agent: Cooper & Dunham, LLP

20080108616 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes,... Agent: Genomics Institute Of The Novartis Research Foundation

20080108615 - Imidazole-2-carboxamide derivatives as raf kinase inhibitors: e

20080108617 - Modulators of pharmacokinetic properties of therapeutics:

20080108618 - Compounds with activity on muscarinic receptors: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.... Agent: Knobbe Martens Olson & Bear LLP

20080108619 - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses: m

20080108620 - Substituted pyrazoles, compositions containing such compounds and methods of use: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.... Agent: Merck And Co., Inc

20080108621 - Aminopterin dosage forms and methods for inflammatory disorders: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted... Agent: Syntrix Biosystems, Inc.

20080108623 - Thienopyrimidine compounds and use thereof: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1′) a halogen, (2′) a hydroxy group, (3′) a C1-4 alkyl and (4′) a C1-4 alkoxy, (2) a phenyl which may have a... Agent: Edwards Angell Palmer & Dodge LLP

20080108624 - Methylene dipiperidine derivatives: The present invention relates to novel methylene dipiperidine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080108625 - Substituted triazole derivatives as oxytocin antagonists: The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).... Agent: Pfizer Inc.

20080108626 - Pyrazole-amine compounds useful as kinase inhibitors: useful for treating p38 kinase-associated conditions, where G, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of... Agent: Louis J. Wille Bristol-myers Squibb Company

20080108622 - Combination therapy for the treatment of pain: The present invention provides synergistic combinations for the treatment of conditions associated with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain associated with migraine. In particular, the present invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with... Agent: Christopher A. Klein King Pharmaceuticals, Inc.

20080108627 - Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them: e

20080108628 - Indolylmaleimide derivatives:

20080108629 - Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a,... Agent: Seed Intellectual Property Law Group Pllc

20080108630 - Substituted triazoles as modulators of ppar and methods of their preparation: The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of... Agent: Townsend And Townsend And Crew, LLP

20080108631 - Human protein tyrosine phosphatase inhibitors an methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent: Needle & Rosenberg, P.c.

20080108632 - Hcv protease inhibitors: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat hepatitis C virus infection.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080108633 - Use 540: This invention relates to new use of pyrazolyl derivatives and pharmaceutically acceptable salts thereof, which have been found to possess analgesic activity and are accordingly useful in the treatment or prophylaxis of pain conditions in the human or animal body, for example in the manufacture of medicaments for the treatment... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080108634 - Novel phenylalanine derivatives: Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to α4 integrin. They are used as therapeutic agents for various diseases concerning α4 integrin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080108635 - Triazolopyrimidine derivatives as adp p2y12 receptor antagonists: e

20080108636 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson Sonsini Goodrich & Rosati

20080108638 - 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists: The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent “chemoattractant receptor-homologous molecule expressed on Th2 cells” antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.... Agent: Dickstein Shapiro LLP

20080108637 - Crystals of phenylalanine derivatives, production method thereof and use thereof: The present invention discloses crystals of phenylalanine derivatives which have a specific structural formula, and particularly crystals which are easy to be used; crystals excellent in preservation stability, humidity resistance or solubility; and crystals which can be manufactured on the industrial scale. The present invention also discloses the production method... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080108639 - Synergistic insecticidal compositions: The present invention provides a synergistic insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists... Agent: Novak Druce Deluca + Quigg LLP

20080108640 - Method of restoring the incretin effect: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion.... Agent: Michael Best & Friedrich LLP

20080108642 - Composition and its use as effective constituent of a medicine having anti-angiogenesis synergy effect: The present invention relates to a composition as effective constituent of a medicine having anti-angiogenesis synergy effect and belongs to the field of medicine compositions. The recipe is composed of matrine and sinomenine hydrochloride with a content ratio of matrine:sinomenine hydrochloride=1:0.05 to 1. The recipe of the present invention has... Agent: Greer, Burns & Crain

20080108641 - Compounds for treating inflammatory disorders, demyelinating disdorders and cancers: e

20080108643 - Method for treating autism: A method for treating autism comprising the step of administering an effective amount of Memantine and dextromethorphan or pharmaceutically acceptable derivatives and/or salts thereof.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20080108644 - Vinca derivatives: The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20080108645 - Dihydrotetrabenazines and pharmaceutical compositions containing them: The invention provides novel isomers of dihydrotetrabenazine, individual enantiomers and mixtures thereof wherein the dihydrotetrabenazine is a 3,11 b-cis-dihydrotetrabenazine. Also provided are methods for the preparation of the novel isomers, pharmaceutical compositions containing them and their use in treating hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic,... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080108646 - Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment: The present invention relates to optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical... Agent: Ladas & Parry

20080108647 - Treatment of hiv and diseases of immune dysregulation: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof including the treatment of HIV and diseases of immune dysregulation.... Agent: Ashok Tankha Of Counsel, Lipton, Weinberger & Husick

20080108649 - Bicyclic modulators of androgen receptor function: wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.... Agent: Heslin Rothenberg Farley & Mesiti, P.c.

20080108648 - Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same: The invention concerns compounds of formula I, a method for preparing said compounds, pharmaceutical compositions containing same and the therapeutic uses thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080108650 - Phosphodiesterase 10a inhibitor: e

20080108651 - Enantiomeric compounds with antibacterial activity: Novel compounds in enantiomeric excess that are inhibitors of bacterial methionyl synthetase (MetRS) are disclosed. Also disclosed are methods for their preparation and their use in therapy as antibacterial agents, and in particular their use in therapy for Clostridium difficile infection.... Agent: Swanson & Bratschun, L.l.c.

20080108652 - Imidazo (4,5-b) pyridine-derivatives as inducible no-synthase inhibitors: v

20080108653 - Tripeptidyl peptidase inhibitors: wherein n is an integer 0 or 1; X represents O; S; or —(CR4R5)m— wherein m is an integer 1 or 2; R4 and R5 are each independently from each other hydrogen or C1-4alkyl; R1 is C1-6alkylcarbonyl optionally substituted with hydroxy; C1-6alkyloxycarbonyl; aminoC1-6alkylcarbonyl wherein the C1-6alkyl group is optionally substituted... Agent: Philip S. Johnson Johnson & Johnson

20080108654 - Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080108655 - Drug composition and method for treating malaria and malignancy: A method of treating a malarial infection includes using orphenadrine as part of treating the infection. The method may use orphenadrine alone or in combination with another antimalarial drug, such as chloroquine, or with plural antimalarial drugs. Use of orphenadrine in this way may also be used in a method... Agent: Kolisch Hartwell, P.c.

20080108656 - Compositions and methods for inhibiting tgf-beta: and pharmaceutically acceptable isomers, salts, hydrates, solvates, and prodrug derivatives thereof, wherein R1, R6, R7, R8, Pg, and n are those defined herein. The present invention also provides pharmaceutical compositions comprising the same and methods for using the same. In particular, compounds of Formula I are useful in modulating TGF-β... Agent: Townsend And Townsend And Crew, LLP

20080108657 - Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one: An ethanol solvate form of (−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride (Form II), a method of making Form II and a composition comprising Form II.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080108660 - Benzimidazolone carboxylic acid derivatives: wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux... Agent: Pfizer Inc.

20080108658 - Methods of promoting osteogenesis: The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor. The invention is directed to methods of treating bone fractures, bone diseases, bone grafting, especially enhancing bone healing following facial reconstruction, maxillary reconstruction, mandibular reconstruction or tooth extraction, enhancing long bone extension, enhancing prosthetic... Agent: Morrison & Foerster LLP

20080108659 - Poly(adp-ribose)polymerase inhibitors: Compounds which inhibit the activity of poly(ADP-ribose)polymerase, compositions containing the compounds and methods of treating diseases using the compounds is disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20080108662 - Biaryloxymethylarenecarboxylic acids as glycogen synthase activator: m

20080108661 - Medicaments: wherein: R1 is phenyl optionally substituted by halogen, cyano, C1-4 alkyl or C1-4 haloalkyl; R2 is hydrogen, C1-6 alkyl or C3-6 cycloalkyl; and R3 is a group having an NH or OH that has a calculated or measured pKa of 1.0 to 8.0; or a pharmaceutically acceptable salt thereof, in... Agent: Fish & Richardson P.c.

20080108663 - Cyclopropyl piperidine glycine transporter inhibitors: The present invention is directed to cyclopropyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neuro-transmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.... Agent: Merck And Co., Inc

20080108664 - Solid-state form of amg 706 and pharmaceutical compositions thereof: The anti-angiogenic drug AMG 706 is provided in amorphous form. Also provided is AMG 706 drug substance wherein the AMG 706 is present, in at least a detectable amount, as amorphous AMG 706. Also provided is an AMG 706-crystallization inhibitor composite comprising particles of amorphous AMG 706 or a AMG... Agent: Amgen Inc.

20080108666 - Heteroaryl (substituted)alkyl n-substituted sulfoximines as insecticides: N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences Llc

20080108667 - Multi-substituted pyridyl sulfoximines and their use as insecticides: Multi-substituted pyridyl sulfoximines are useful as insecticides.... Agent: Dow Agrosciences Llc

20080108665 - Use of n-substituted sulfoximines for control of invertebrate pests: Methods to control certain invertebrates including insects in agricultural, urban, animal health, and industrial systems by directly or systemically applying to a locus where control is desired an effective amount of a compound of N-substituted sulfoximines.... Agent: Dow Agrosciences Llc

20080108668 - Substituted azole compounds and its preparation and use thereof: The compounds of present invention, having broad spectrum fungicidal activity, applied for controlling various disease in plants. For example they have good activity against the diseases such as cucumber downy mildew, cucumber grey mold, cucumber powdery mildew, tomato early blight, tomato late blight, phytophthora blight of pepper, grape downy mildew,... Agent: Smith, Gambrell & Russell

20080108670 - Non-systemic control of parasites: Use of agonists and antagonists of the nicotinergic acetylcholine receptors of insects for the non-systemic control of parasitic insects, such as fleas, lice and flies, on humans and on animals.... Agent: Norris, Mclaughlin & Marcus, Pa

20080108671 - Non-systemic control of parasites: Use of agonists and antagonists of the nicotinergic acetylcholine receptors of insects for the non-systemic control of parasitic insects, such as fleas, lice and flies, on humans and on animals.... Agent: Norris, Mclaughlin & Marcus, Pa

20080108669 - Use 541: This invention relates to new use of pyrazolyl derivatives and pharmaceutically acceptable salts thereof, which have been found to possess analgesic activity and are accordingly useful in the treatment or prophylaxis of pain conditions in the human or animal body, for example in the manufacture of medicaments for the treatment... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080108672 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Millen, White, Zelano & Branigan, P.c.

20080108673 - Prevention and treatment of obesity: O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.... Agent: Fish & Richardson Pc

20080108674 - Cationic antiseptic and dye formulation: Aqueous antiseptic solutions and compatible dyes and methods for making and using such solutions are provided. Specifically, in one embodiment, the present invention relates to an antiseptic solution comprising a micellular complex consisting of a cationic excipient and an anionic dye. The antiseptic solution further includes a cationic antiseptic.... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20080108675 - Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders: u

20080108676 - Benzothiazolecarboxamides: The present invention relates to new compounds of formula I, (I) wherein R1 to R4, m, n and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to a new intermediate used in the preparation thereof, pharmaceutical formulations containing... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080108677 - Thioxothiazolidinone compounds for use as pharmaceuticals: The present invention relates to thioxothiazolidinone compounds for use as pharmaceuticals, to pharmaceutical compositions comprising these compounds, and to the use of said small-molecule compounds for the manufacture of pharmaceutical compositions for the treatment of conditions dependent on leukocyte cell migration, such as leukaemia and inflammatory diseases. Said compounds inhibit... Agent: Birch Stewart Kolasch & Birch

20080108678 - Cyclic derivatives as modulators of chemokine receptor activity: e

20080108679 - Isoxazolic derivative to relieve neuropathic pain: The present invention relates to new pharmaceutical uses of an isoxazolic derivative or a pharmaceutically acceptable salt thereof in the preparation of a medicament useful for treating the neuropathic pain.... Agent: Lucas & Mercanti, LLP

20080108680 - Fungicidally active compound combinations: Active compound mixtures comprising ipconazole and at least one further fungicidally active compound are highly suitable for protecting industrial materials against colonization and destruction by microorganisms.... Agent: Lanxess Corporation

20080108681 - Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions: Compositions comprising allantoin and an acceptable carrier and methods of using such compositions to increase pro-collagen synthesis in skin are disclosed. Compositions of the present invention may be used to decrease the signs of skin aging such as wrinkles and fine lines. Compositions of the present invention may be topically... Agent: In Re: Alticor Inc. 28533 Brinks, Hofer, Gilson & Lione

20080108682 - Method for manufacturing enantiomeric imidazole compounds: The invention relates to a method for manufacturing R-(−)-sertaconazole mononitrate. The invention also relates to R-(−)-sertaconazole mononitrate hemiacetonate.... Agent: Birch Stewart Kolasch & Birch

20080108683 - 4-phenylthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy: The invention relates to novel derivatives of 4-phenylthiazoles and 4-phenylimidizoles and the use thereof as medicaments. The invention especially relates to the following compounds: butyl-2-[4-(4-aminophenyl)-1H-imidizol-2-yl]ethyl-carbamate, and 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, and the salts of the same.... Agent: Hunton & Williams LLP Intellectual Property Department

20080108684 - Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor: Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080108685 - Novel use for alpha sympathomimetics having a 2-imidazoline structure: The invention relates to the use of α-sympathomimetics having a 2-imidazoline structure for the preparation of a medicament for the prophylaxis and/or treatment of viral diseases.... Agent: Millen, White, Zelano & Branigan, P.c.

20080108686 - N-(ortho-phenyl)-1-methyl-3-difluoromethylpyrazole-4-carboxanilides and their use as fungicides: e

20080108687 - Ramipril formulation: A Ramipril formulation which is suitably stabilised to control the degradation to the active metabolite ramiprilat.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080108688 - Ramipril formulation: A Ramipril formulation which is suitably stabilised to control the degradation to the active metabolite ramiprilat.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080108689 - Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists: The present invention is directed to certain hydropyranopyrrolidine compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formations comprising these compounds as active ingredients and the use of the compounds and their formulations in... Agent: Merck And Co., Inc

20080108690 - Inhibitors of cyclin dependent kinases and their use: wherein R1, R2, R3, R4, R5, R6, R7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of... Agent: Frommer Lawrence & Haug

20080108691 - Open-chain prolyl urea-related modulators of androgen receptor function: wherein R1, R2, R3, X, Y, n and G are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds. Other embodiments are also... Agent: Heslin Rothenberg Farley & Mesiti, P.c.

20080108692 - Organoselenium compound for cancer chemoprevention: A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis... Agent: Mueting, Raasch & Gebhardt, P.a.

20080108693 - Crystalline forms of docetaxel and process for preparation thereof: New anhydrous crystalline form of docetaxel and process of making anhydrous docetaxel and docetaxel trihydrate are provided.... Agent: Cohen, Pontani, Lieberman & Pavane

20080108694 - Novel macrocycles and uses thereof: w

20080108695 - Method of treating asthma, allergic rhinitis, and skin disorders: The use of 5,6,7-trihydroxyheptanoic acid and analogs is disclosed for the treatment of asthma, allergic rhinitis, and skin disorders such as allergic dermatitis, contact hypersensitivity, urticaria (hives), rosacea, or psoriasis.... Agent: Alcon

20080108696 - Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases: Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080108697 - Device for packaging an oxaliplatin solution: The invention concerns an assembly consisting of an aqueous oxaliplatin solution and a glass flask containing same, characterised in that the surface/volume ratio of the flask, expressed in mm2/mm3, is less than 0.26.... Agent: Nixon & Vanderhye, Pc

20080108698 - Nutrient supplement and use of the same: The present invention generally relates to enhancement and recovery of muscle performance in a state of stress induced by physical exercise, disease or trauma. More particularly the invention relates to means for improved muscle performance and for providing more efficient muscle recovery after physical or traumatic stress. The present invention... Agent: Seyfarth Shaw

20080108699 - Composition comprising dihomo-y-linolenic acid (dgla) as active ingredient: The present invention provides a composition, such as a food and pharmaceutical agent, which comprises dihomo-γ-linolenic acid, and which has the effect of preventing or treating skin diseases; a composition such as a food and pharmaceutical agent which comprises dihomo-γ-linolenic acid and which has the effect of preventing or treating... Agent: Drinker Biddle & Reath (dc)

20080108701 - Diagnostic agent for tumor: e

20080108700 - External preparation: It is an object of the present invention to provide an external preparation having enhanced transdermal penetration of a mast cell degranulation inhibitor. It is also an object of the present invention to provide a method for improving the photostability of a preparation containing a mast cell degranulation inhibitor. The... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080108702 - Use of acetyl-leucine for preparing a drug for treating balance disorders: The invention concerns the use of acetyl-leucine for preparing a drug for treating acute deafferentiation in patients whose vestibular deficit is less than (88%), advantageously less than (75%) to caloric tests.... Agent: Birch Stewart Kolasch & Birch

20080108703 - Methods for improving bioavailability of a renin inhibitor: The present invention provides a method for improving the bioavailability of a renin inhibitor, preferably, of a δ-amino-γ-hydroxy-ω-aryl-alkanoic acid derivative, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of a renin inhibitor, or a pharmaceutically acceptable salt thereof, and an efflux... Agent: Novartis Corporate Intellectual Property

20080108704 - Hydroalcoholic compositions thickened using polymers: An antimicrobial hydroalcoholic composition comprising hydroalcoholic solvent system comprising a lower alcohol and water in a weight ratio of at least about 50:50; a thickener system comprising at least one cationic or nonionic polymeric thickener that is solid at ambient temperature; and a secondary antimicrobial agent.... Agent: 3m Innovative Properties Company

20080108706 - Chemical resection of pancreas: wherein: R1 and R2 may be the same or different and are alkyl having 1 to 6 carbon atoms or aryl or aralkyl having up to 12 carbon atoms; a, b, d and e may be the same or different and are integers from 1 to 4; and c is... Agent: Miles & Stockbridge Pc

20080108705 - Treatment of diabetes with copper bunding compounds: Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.... Agent: Duane Morris LLP

20080108707 - Antiangiogenic, antitumor, chemopreventative agents: Pharmaceutical compositions and methods of treating conditions such as angiogenic-, neoplastic-, and cancer-related conditions and skin conditions are disclosed. The methods include administering to a host in need of treatment an effective amount of at least one honokiol-type compound and/or at least one magnolol-type compound. In addition, the pharmaceutical compositions... Agent: Womble Carlyle Sandridge & Rice, Pllc

20080108708 - Method for producing albumin conjugates containing gyrase inhibitors: The present invention concerns gyrase inhibitor-protein conjugates and in particular gyrase inhibitor-albumin conjugates, pharmaceutical preparations comprising gyrase inhibitor-protein conjugates in particular for the treatment and/or prophylaxis of inflammatory processes and/or tumours as well as methods for their production.... Agent: Morris Manning Martin LLP

20080108709 - Cold-preparable, low-viscosity and prolonged cosmetic emulsions with coemulsifiers containing cationic groups: PEG-free, cold-preparable, prolonged-stability, low-viscosity, fine oil-in-water emulsions, their preparation from preferably clear oil phases or via preferably clear to transparent microemulsion-like concentrates, the corresponding oil phases or microemulsion-like concentrates and the use of the inventive emulsions for producing cosmetic, dermatological, pharmaceutical or industrial formulations, especially for the production of impregnating... Agent: Scully Scott Murphy & Presser, Pc

20080108710 - High-potency sweetener composition with preservative and compositions sweetened therewith: The present invention relates generally to sweetener compositions comprising non-caloric or low-caloric high-potency sweeteners and methods for making and using them. In particular, the present invention relates to different sweetener compositions comprising at least one non-caloric or low-caloric natural and/or synthetic high-potency sweetener, at least one sweet taste improving composition,... Agent: Sutherland Asbill & Brennan LLP

20080108711 - Use of the slug gene or the replication, transcription or expression products thereof in the identification, diagnosis, prevention or treatment of the spread of cancer and/or the development of metastasis: The invention relates to the Slug gene, the replication, transcription or expression products thereof and products related with the regulation of said Slug gene or with the regulation, elimination or degradation of the expression or translation products of same, which can be used in the identification, prevention or treatment of... Agent: Morrison & Foerster LLP

20080108713 - Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a... Agent: Celera, An Applera Business Unit

20080108712 - Nucleotide sequence associated with acute coronary syndrome and mortality: The present invention provides methods for diagnosing and/or treating subjects that either have or are at risk for developing acute coronary syndrome. In addition, the invention provides isolated nucleotide sequences and arrays comprising the nucleotide sequences that may be used for treatment and/or diagnosis of subjects that either have or... Agent: Polsinelli Shalton Flanigan Suelthaus Pc

20080103086 - Methods for the treatment of diseases associated with the secretion of hmgb1: The present invention relates to a pharmaceutical composition comprising an antagonist of the phosphorylation of HMGB1, and a method for treating a condition associated with activation of the inflammatory cytokine cascade comprising administering an effective amount of an said antagonist of HMGB1 phosphorylation.... Agent: Jhk Law

20080103088 - Alternative oxidase and uses thereof: The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in Drosophila has been shown to confer spectacular cyanide-resistance to mitochondrial substrate oxidation, alleviate... Agent: Marshall, Gerstein & Borun LLP

20080103087 - Compositions and methods to control angiogenesis with cuperdoxins: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080103089 - Compounds, compositions, formulations and process for preparation thereof and method of treatment and management of acidity and related disorders: Novel antacid preparations, methods of preparation of the same and a method of treating acidity related disorders using the said novel antacid composition are described. The antacid composition of this invention are based on use of proteins and their derivatives including their hydrolysates and enzymatic treatment products such as plasteins... Agent: Nath & Associates

20080103091 - Bi-functional peptides for multiple sclerosis treatment and diagnosis: Novel bifunctional peptides useful in the treatment and/or diagnosis of EAE or MS. The peptides have a first peptide portion derived from an epitope of myelin proteolipid protein, myelin oligodendrocyte glycoprotein, or oligodendrocyte-specific peptide and a second peptide portion derived from CD11a (LFA-1 alpha subunit), CD18 (LFA-1 beta subunit), CD154... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080103097 - Glp-1 derivatives ii: The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.... Agent: Novo Nordisk, Inc. Patent Department

20080103096 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of... Agent: Eli Lilly & Company

20080103095 - Stress protein compositions and methods for prevention and treatment of cancer and infectious disease: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an... Agent: Karen S. Canady Canady & Lortz LLP

20080103103 - Reagents and methods to treat ocular diseases and infection: The invention provides compositions and methods of treating an ocular condition by administering to an eye of a patient having an ocular condition an effective amount of a catechin or polyphenol. The compositions and methods can be used to treat ocular conditions such as ocular infection, ocular inflammation, ocular cancer... Agent: Mcdermott, Will & Emery

20080103106 - Compositions and their uses directed to il-4r alpha: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to... Agent: Knobbe, Martens, Olson & Bear, LLP

20080103107 - Screening methods: The present invention provides materials and methods relating to screening for compounds useful in the treatment of Alzheimer's disease and related conditions. In particular, screening methods using tyrosine kinases are provided, as are methods relating to the role of tyrosine kinases as therapeutic targets.... Agent: Dann, Dorfman, Herrell & Skillman

20080103108 - Targeted artificial gene delivery: Novel and improved compositions and methods for gene therapy are provided. In particular, a targeted artificial gene delivery (“TAGD”) vehicle is provided, comprising a multifunctional artificial surface moiety surrounding a recombinant viral particle (nucleocapsid) or recombinant core for gene delivery.... Agent: Ropes & Gray LLP

20080103110 - Compounds: The invention provides a water-soluble prodrug compound comprising a therapeutically effective moiety coupled via a metabolically cleavable bond to a protein binding moiety, wherein said therapeutically effective moiety has an anticancer, antiinflammatory, antiinfective or antipain effect, said protein binding moiety binds non-covalently to blood proteins, and the protein binding of... Agent: Sughrue Mion, PLLC

20080103111 - Smoking cessation treatment with appetite suppression: A multi-component compound for the simultaneous treatment of nicotine addiction and the side effects of nicotine withdrawal, such as excessive appetite. The first component is a bivalent negative sulfur compound in an amount effective to control nicotine craving or the withdrawal symptoms resulting from nicotine withdrawal. The bivalent negative sulfur... Agent: John C. Smith, Esq.

20080103114 - Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions: The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane... Agent: Jones Day

20080103090 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080103092 - Methods for intradermal, transdermal or transmucosal delivery of biologically active substances: This invention relates to method for intradermal, transdermal or transmucosal delivering a biologically active substance to a mammal in need thereof, which method comprises a step of co-administering to said mammal with the biologically active substance an effective amount of an absorption enhancer, which is water comprising from about 99.760... Agent: Notaro And Michalos

20080103093 - Methods of treating cartilage defects: The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.... Agent: Ropes & Gray LLP

20080103094 - Targeted delivery of drugs for the treatment of viral infections: Conjugates of transferrin or transcobalamin with anti-viral agents are useful in the treatment of viral infections. Suitable anti-viral agents include apoptosis inducing compounds, compounds which inhibit the replication of the virus, a cytotoxic antibiotic, an alkylating agent, a plant toxin, and a bacterial mutant toxin. Transferrin or transcobalamin is preferably... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080103099 - Apoptin-associating protein: The invention relates to the field of apoptosis. The invention provides novel therapies, for example, novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is completely or partially non-functional.... Agent: Trask Britt

20080103098 - Recombinant expression of proteins in a disulfide-bridged, two-chain form: Polypeptides or proteins are produced as a disulfide bridged dichain by recombinant expression in E. coli host cells and exert biologic activity as such a dichain. A C-terminal amino acid of the first chain is Arg or Lys. The second chain has N-terminally 1 to 20 amino acid residues and... Agent: Gudrun E. Huckett Draudt

20080103100 - Materials and methods for the treatment of celiac disease: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20080103101 - Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells: A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.... Agent: Quarles & Brady LLP

20080103102 - Therapeutic compositions and methods of treatment with capsianoside-type compounds: The present invention discloses the use of certain compounds as therapeutic agents, and in particular as analgesics and anti-inflammatory agents. Such compounds include, for example, certain diterpene monoglycosides and diterpene diglycosides. The compounds of the present invention may be synthesized or isolated from the fruit of the genus Capsicum, and... Agent: Keith R. Lange

20080103104 - Treatment of cancer: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20080103105 - Hmg coa reductase mediated modulation of neurogenesis: The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of an HMGCR modulating agent, optionally in combination with one or more other neurogenic agents,... Agent: Townsend And Townsend And Crew, LLP

20080103109 - Vectors for tissue-specific replication: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per... Agent: Ropes & Gray LLP

20080103112 - Glucan preparations: Particulate β-glucan is solubilized at elevated pressure and temperature to form soluble β-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent.... Agent: Biopolymer Engineering , Inc. Dba Biothera , Inc

20080103113 - Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex: The present invention relates to methods to use non-steroidal ligands in nuclear receptor-based inducible gene expression system to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising:... Agent: Sughrue Mion, PLLC

20080103115 - Phosphonate compounds: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.... Agent: Dla Piper US LLP

20080103116 - Method of treatment and compositions of d-chiro inositol and phosphates thereof: The present invention relates to the use of D-chiroinositol or a phosphate thereof in combination with folate for the reduction or prevention of congenital deformations such as anorectal malformations, neural tube defects, cleft-lip, cleft palate, and other birth defects. The invention further relates to the use of D-chiroinositol or a... Agent: Irving M. Fishman C/o Cohen, Tauber Spievack & Wagner

20080103117 - Treatment product for animals and means for preparing same: e

20080103118 - Composition for improving blood cholesterol levels: A nutritional composition for improving blood cholesterol by jointly and simultaneously inhibiting cholesterol absorption, decreasing blood LDL levels, increasing blood HDL levels and interfering with HMG-CoA reductase synthesis or degradation in an individual comprising, therapeutically effective amounts of plant sterols or plant stanols or derivatives thereof, procyanidins, policosanol and niacin... Agent: Torys LLP

20080103119 - Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists: n

20080103120 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Synnestvedt & Lechner, LLP

20080103121 - Cephalosporin derivative formulation: The present invention relates to a freeze-dried formulation for cephalosporin derivatives having increased stability and a method for preparing such a formulation using certain excipients for stabilizing the formulation.... Agent: Philip S. Johnson Johnson & Johnson

20080103122 - Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis: A pharmaceutical combination comprising an effective amount of at least one cholesterol absorption inhibitor and at least one microsomal triglyceride transfer protein inhibitor (MTP).... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080103124 - Cefdinir-containing pharmaceutical composition: A pharmaceutical composition with an enhanced bioavailability, particularly improved an oral absorption, comprising cefdinir or a pharmaceutically acceptable salt thereof and aminoalkyl methacrylate copolymer E is disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080103125 - Heterocylic antiviral compounds: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080103126 - Medicinal compositions improving brain function and method for improving brian function: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103123 - New compounds: and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein one of W1 and W2 is N and the other is CR12. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of... Agent: Edwards Angell Palmer & Dodge LLP

20080103127 - Methods for treating disruptive behavior disorders: d

20080103128 - Lactams substituted by cyclic succinates as inhibitors of abetta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080103129 - Heterocyclic derived metalloprotease inhibitors:

20080103130 - Benzazepin-2(1h)-one derivatives:

20080103131 - Therapeutically active thiophenepyrimidinone compounds and their use: Thiopheneprymidinone compounds useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.... Agent: Crowell & Moring LLP Intellectual Property Group

20080103132 - Fused heterocyclic compounds: Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080103133 - 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives: r

20080103134 - Use of selected cgrp-antagonists in combination with other antimigraine drugs for the treatment of migraine: The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103135 - Phenylalkynes: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20080103136 - Novel fused imidazole derivative: b

20080103137 - Deazapurines and uses thereof:

20080103138 - Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions: wherein the groups R1 to R4 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103139 - 3-carbamoyl-2-pyridone derivative: e

20080103142 - Benzotriazole kinase modulators:

20080103140 - Cyclohexylamides as dopamine d3, d2 and 5ht1a antagonists: The present invention relates to new dopamine D3 and D2 and serotonin 5-HT1A receptor subtype preferring ligands of formula (I); wherein A represents alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or a group of formula —NR1R2, wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, alkenyl, aryl, heteroaryl or... Agent: Darby & Darby P.C.

20080103141 - New compounds: and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein W1 and W3 are N and W2 and W4 are CR12, or W1 and W3 are CR12 and W2 and W4 are N. The invention also relates to pharmaceutical compositions comprising these compounds, and to... Agent: Edwards Angell Palmer & Dodge LLP

20080103143 - Novel heteroaryl carboxamides: d

20080103144 - Fungicidal mixtures based on amide compounds and morpholine or piperidine derivatives:

20080103145 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. Examples of such compounds include reboxetine, and more particularly racemic reboxetine. The methods generally include administration of... Agent: James J. Napoli Marshall O'toole Gerstein Murray & Borun

20080103146 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about... Agent: James J. Napoli Marshall O'toole Gerstein Murray & Borun

20080103147 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. Examples of such compounds include reboxetine, and more particularly racemic reboxetine. The methods generally include administration of... Agent: James J. Napoli Marshall O'toole Gerstein Murray & Borun

20080103148 - Cyclic pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103149 - Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications: e

20080103150 - Triazoles as farnesyl transferase inhibitors: a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(═O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; =Z1-Z2=Z3-... Agent: Philip S. Johnson Johnson & Johnson

20080103151 - Heterocyclic compounds and their uses as therapeutic agents: This invention is directed to heterocyclic compounds that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080103152 - Novel diazabicyclononene derivative: The invention relates to a novel 3,9-diazabicyclo[3.3.1]nonene derivative and the enantiomers thereof and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing at least one compound of formula (I) or... Agent: Thomas Hoxie

20080103153 - Combination of brimonidine and timolol for topical ophthalmic use: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.... Agent: Allergan, Inc.

20080103154 - 3, 4-dihydro-2(ih)-quinolinone and 2(1h)-quinolinone derivatives: The present invention relates to novel 3,4-dihydro-2(1H)-quinolinone and 2(1H)-quinolinone derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by atypical antipsychotic agents.... Agent: Edwards Angell Palmer & Dodge LLP

20080103155 - Pharmaceutical compositions for the treatment of sexual disorders ii: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103156 - Bicyclic heteroaromatic compounds: e

20080103158 - Methods for treating delaying the progression of alzheimer's disease with heterocyclic compounds: Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103157 - Methods for treating depression, neurodegeneration, inhibiting amyloid beta deposition, delaying senescence, and extending life spans with heterocyclic compounds: Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103159 - Composition comprising ocaperidone: The present invention relates to a composition comprising ocaperidone as an active substance and an effective amount of water-soluble polymers to increase solubility of ocaperidone. The present invention further relates to a therapeutic system for ocaperidone with a compartment for the drug formulation comprising said composition, and to a process... Agent: Philip S. Johnson Johnson & Johnson

20080103160 - Protein phosphatase inhibitors: A method of inhibiting protein tyrosine phosphatase in a subject includes administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone, phenyl isothiazolone, or analog thereof to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20080103161 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof: Ra, Rb, Rc, A, B, C, D, E and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103162 - Antipruritics: The present invention relates to an antipruritic agent comprising a nociceptine antagonist as an active ingredient. The nociceptine antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney... Agent: Dreier LLP

20080103163 - Antipruritics: The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney... Agent: Dreier LLP

20080103164 - Useful compounds for hpv infection: The present invention relates to compounds that are useful in the treatment of human papillomaviruses, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080103165 - Ppar mediated modulation of neurogenesis: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more other... Agent: Townsend And Townsend And Crew, LLP

20080103166 - Remedy for psychoneurotic diseases: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.... Agent: Wolf Greenfield & Sacks, P.C.

20080103168 - Novel 3-thia-10-aza-phenanthrene derivatives: m

20080103167 - Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes: The present invention provides compounds of the formula (I), which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type... Agent: Novartis Institutes For Biomedical Research, Inc.

20080103169 - Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same: The present disclosure relates to pharmaceutical compositions comprising combinations of proton pump inhibitors, their salt forms or related compounds and at least one other pharmaceutically active agent. Methods of using such compositions, including methods of and an apparatus for administering such compounds, are also provided... Agent: Mayer Brown LLP

20080103170 - Nicotinic acetylcholine receptor ligands: e

20080103171 - Stable particular pharmaceutical composition of solifenacin or salt thereof: The present invention relates to the provision of a stable particulate pharmaceutical composition of solifenacin or a salt thereof, which is in a spherical shape suitable for coating and in which degradation with time can be inhibited when a pharmaceutical preparation of solifenacin or a salt thereof is supplied to... Agent: Sughrue-265550

20080103172 - Imidazole substituted pyrazole kinase inhibitors: e

20080103173 - Compounds having activity at nk3 receptor and uses thereof in medicine:

20080103175 - 7-((1h-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline:

20080103174 - Ether derivatives:

20080103176 - Substituted hydroxyethylamines: This invention is directed to compounds of the formula (I), as defined herein. The compound of formula I may be used, for example, to treat a disorder or condition that may be treated by inhibiting 13-secretase.... Agent: Pfizer Inc Steve T. Zelson

20080103177 - New use of iloperidone: The invention relates to the use of iloperidone in the treatment of affective disorders, including bipolar mood disorders.... Agent: Hoffman Warnick & D'alessandro, LLC

20080103178 - N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives: in which, R stands for a dihydroxy-substituted C1-C6 alkyl group, and Cy stands for an optionally substituted C6-C10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic... Agent: Merck And Co., Inc

20080103179 - Combination therapy: The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate compound (e.g., topiramate) or an anticonvulsive sulfonylurea... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080103180 - Ccr9 inhibitors and methods of use thereof: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula... Agent: Millennium Pharmaceuticals, Inc.

20080103181 - Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases: Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.... Agent: Bingham Mccutchen LLP

20080103182 - Indazole derivatives: t

20080103183 - New imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors:

20080103184 - Compositions and methods for treating hair loss using non-naturally occurring prostaglandins: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.... Agent: Michael Best & Friedrich LLP

20080103185 - Process for producing thiazolidinedione compound and production intermediate thereof: As described above, a process for producing a compound represented by the general formula (A) or a salt thereof, comprising converting 4-[(2,4-dioxothiazolidin-5-yl)methyl]phenoxyacetic acid represented by the following formula into a compound of the general formula (I), wherein X=a halogen atom; then reacting the compound with a compound represented by the... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080103186 - Novel crystalline forms of an antiviral benzimidazole compound: The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H benzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080103187 - Tgf-beta gene expression inhibitor: A TGF-β gene expression inhibitor containing a pyrrole-imidazole polyamide having N-methylimidazole unit (hereinafter also referred to as Py), N-methylimidazole unit (hereinafter also referred to as Im) and γ-aminobutyrate unit which can be holded into an U-shaped conformation at the γ-aminobutyrate unit in the minor groove in a double helix region... Agent: Birch Stewart Kolasch & Birch

20080103188 - Novel bicyclic compounds as modulators of androgen receptor function: T

20080103189 - Preparation and utility of substituted indoles: Disclosed herein are substituted indoles of Formula I, processes of preparation there of, pharmaceutical compositions thereof, and methods of their use there of.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080103190 - Thrombopoietin activity modulating compounds and methods: Disclosed herein are compounds, pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.... Agent: Knobbe Martens Olson & Bear LLP

20080103191 - Entacapone-derivatives: Pharmaceutical composition comprising one or more entacapone derivatives and one or more pharmaceutically acceptable carriers, a process for producing the pharmaceutical composition, specific entacapone derivatives, a process for the preparation of entacapone derivatives, and the use of the entacapone derivatives for the preparation of a medicament.... Agent: Harness, Dickey & Pierce, P.L.C

20080103192 - Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer: Compounds having an artemisinin-related endoperoxide moiety covalently coupled to a hydrazone moiety through a linker. Compositions and methods for treating cancer using the compounds.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080103193 - Methods for making compositions and compositions for treating pain and cachexia: The present invention pertains to methods for making compositions and compositions for treating pain and cachexia or AIDS wasting. In particular, the instant invention employs methods for making Δ9-tetrahydrocannabinol (Δ9-THC) and Δ9-tetrahydrocannabinolic acid (Δ9-THCA) from Cannabis sativa, and compositions for the treatment of these diseases.... Agent: Aphios Corporation

20080103194 - Anti-first-pass effect compounds: Safe, effective first-pass inhibiting compounds and citrus-derived substances are provided. Formulations containing the compounds are also provided as are methods for inhibiting the first pass effect.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103195 - Compounds from antrodia camphorata for inhibiting the growth of cancer tumor cells: The present invention relates a compound for inhibiting the growth of tumor cells. More specifically, the compound of the present invention is 4,7-dimethoxy-5-methy-1,3-benzodioxole. 4,7-dimethoxy-5-methy-1,3-benzodioxole of the present invention is used for inhibiting the growth of tumor cells of breast cancer, liver cancer, and prostate cancer, and the pharmaceutical composition comprises... Agent: Birch Stewart Kolasch & Birch

20080103196 - Novel diterpenes from the fruiting body of antrodia camphorata and pharmaceutical compositions thereof: e

20080103197 - Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics:

20080103198 - Methods for treatment of cochlear and vestibular disorders: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20080103199 - Treatment of pervasive developmental disorders: e

20080103200 - Levodopa prodrugs, and compositions and uses thereof: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080103201 - Novel alpha-glucosidase inhibitor from tabernaemontana dichotoma: This invention is directed to a novel pharmacological property of β-Amyrin acetate derived from Tabernaemontana dichotoma as a potent α-glycosidase inhibitor, which has not been reported before. The present discovery also provides for the use of this compound as a new oral hypoglycemic drug in the treatment of type II... Agent: Sarfaraz K. Niazi

20080103202 - Method of preparing creatine ester salts and uses thereof.: This invention discloses the method of preparation of creatine ester-salts. Creatine is an extremely popular ergogenic aid, and is found most often in the form of creatine monohydrate. Creatine monohydrate is poorly soluble in water however and while esters gain solubility, there functionality is greatly decreased. The material can be... Agent: Amin Hallihan, LLC

20080103203 - Skin disinfectant: The skin disinfectant, which is able to sterilize skin by the action of a surfactant without damaging skin health conditions, contains water, from which polyvalent cations are removed and to which a sodium ion is added, and a surfactant. The surfactant is, for example, a fatty acid salt. When the... Agent: Birch Stewart Kolasch & Birch

20080103204 - Method of modulating cellular activity and agents useful for same: Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.... Agent: Bozicevic, Field & Francis LLP

20080103205 - Pesticidal compositions and methods of use: The present invention provides methods of protecting plants and other multicellular organisms from pests. The methods use substituted organic acid or substituted anthracene compounds, which act to alter the activity of one or more anion transporters in the pests. Among the pests treated are nematodes and insects. Methods of screening... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20080103206 - Acetaminophen / ibuprofen combinations and method for their use: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about... Agent: Philip S. Johnson Johnson & Johnson

20080103207 - Topical ceramide compositions and methods of use: Ceramide NS and butylene glycol can form a topical composition in which the ceramide NS is lamellar. The topical compositions can be used in a formulation such as a lotion, gel, or cream and can be used to treat an aging-related skin condition, dry skin, skin irritation, skin wrinkles, or... Agent: Darby & Darby P.C.

20080103208 - Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof: The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular... Agent: Wilson Sonsini Goodrich & Rosati

20080103209 - Compounds and methods for treating non-inflammatory pain using ppar alpha agonists: Compositions and methods for treating noninflammatory pain, including but not limited to, neuropathic pain by using peroxisome proliferator activated receptor a (PPARa) agonists to treat a subject having such pain are described. The agonists may be used with additional therapeutic agents such as an inhibitor of fatty acid amide hydrolase... Agent: Townsend And Townsend And Crew, LLP

20080103210 - wide spectrum disinfectant: The invention discloses methods of making and uses for wide spectrum disinfectants including as components an alcohol, O-phenylphenol, chlorhexidine gluconate, nonoxynol-9, benzalkonium chloride, and deionized double distilled water wherein on a weight/volume ratio the alcohol comprises from 50% to 80%, the O-phenylphenol comprises from 0.1% to 0.8%, the chlorhexidine gluconate... Agent: Porter, Wright, Morris & Arthur LLP Attn: Intellectual Property Department

20080103211 - Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina: Compositions and methods for treating disorders of the outer retina with β-adrenoceptor antagonists are disclosed.... Agent: Alcon

20080103212 - Treatment of fruit in storage facility with solid derived diphenylamine anti scald agent: Techniques for melting and forming aerosols from solid diphenylamine are disclosed. Solid diphenylamine in block, flake or powder form is convenient to ship and to handle. Solid diphenylamine is melted by controlled techniques to form a substantially pure liquid stream of diphenylamine. The molten or liquid stream of diphenylamine is... Agent: Steven D. Boyd Arkema Inc.

20080103213 - Liposomal curcumin for treatment of neurofibromatosis: The present invention provides a compositions and methods for the treatment of Neurofibromatosis Type 1 and 2, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system to target... Agent: Chalker Flores, LLP

20080103214 - Novel composition for easing human childbirth: The present invention relates to a composition having a lubricant effect for use in particular during human vaginal delivery.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080103215 - Screening method: The present invention provides a method of screening a compound or its salt that alters binding properties of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and a ligand capable of... Agent: Edwards Angell Palmer & Dodge LLP